

1 **Clinical Practice Guideline: Lymphedema**
 2
 3 **Date of Implementation: October 18, 2012**
 4
 5 **Product: Specialty**
 6
 7

8 **Table of Contents**

9 GUIDELINES 1
 10 DESCRIPTION 3
 11 Duration and Frequency 4
 12 Contraindications..... 4
 13 GENERAL BACKGROUND 4
 14 EVIDENCE REVIEW 5
 15 Complete Decongestive Therapy (CDT), Manual Lymphatic Drainage (MLD), and Compression
 16 Methods 6
 17 Other Treatments19
 18 Low Level Laser Therapy (LLLT)19
 19 Exercise21
 20 Measurement of Lymphedema26
 21 PRACTITIONER SCOPE AND TRAINING27
 22 References28

23
 24 **GUIDELINES**

25 **Medically Necessary**

26 American Specialty Health – Specialty (ASH) considers complex lymphedema therapy
 27 (complete decongestive therapy) medically necessary for the treatment of intractable
 28 lymphedema when **ALL of the following** are met:

- 29 • Documented failure of a reasonable course of conservative medical management
 30 that includes home exercises, limb elevation, and compression garments.
- 31 • The lymphedema is directly responsible for impaired functioning in the affected
 32 limb.
- 33 • The complex lymphedema therapy is prescribed by or under the supervision of an
 34 appropriate healthcare provider.

35
 36 **Not Medically Necessary**

37 Vasopneumatic compression device use as part of complex lymphedema therapy is
 38 considered not medically necessary.

1 Considered Medically Necessary when criteria in the applicable policy statements listed
 2 above are met:

3

4 **CPT® Codes and Descriptions**

CPT® Code	CPT® Code Description
97140	Manual therapy techniques (e.g., mobilization/manipulation, manual lymphatic drainage, manual traction), 1 or more regions, each 15 minutes
97535	Self-care/home management training (e.g., activities of daily living (ADL) and compensatory training, meal preparation, safety procedures, and instructions in use of assistive technology devices/adaptive equipment) direct one-on-one contact, each 15 minutes
29581	Application of multi-layer compression system; leg (below knee), including ankle and foot
25984	Application of multi-layer compression system; upper arm, forearm, hand, and fingers

5

6 **HCPCS Codes and Descriptions**

HCPCS Code	HCPCS Code Description
S8430	Padding for compression bandage, roll
S8431	Compression bandage, roll
S8950	Complex lymphedema therapy, each 15 minutes

7

8 Multi-layered, sustained, graduated, high compression bandage systems (CPT® code
 9 29581- Application of multi-layer compression system; leg (below knee), including ankle
 10 and foot and CPT® code 29584 - Application of multi-layer compression system; upper
 11 arm, forearm, hand, and fingers) are used primarily to treat lymphedema and venous or
 12 stasis ulcers. A number of graduated, high-compression bandage systems products have
 13 been developed, including Profore®, Dyna-Flex®, Surepress®, Setopress®, and other
 14 similar product systems.

15

16 Providers should note that the treatment of lymphedema with the application of high
 17 compression bandage systems continues to be non-covered by Medicare. However, a brief
 18 period (i.e., three or fewer sessions if no new specific issues are identified) of patient and/or
 19 caregiver education for home management of lymphedema with compression wrap
 20 applications may be medically necessary and reimbursable. Medical necessity for the

1 education must be clearly indicated in the patient's record and must meet the code
 2 descriptor requirements for CPT® 97535, supporting home management training. S8430 –
 3 padding for compression bandage, roll and S8431 – compression bandage, roll may be
 4 appropriate and allowable per health plan benefit.

5 6 **DESCRIPTION**

7 Complex lymphedema therapy (CLT) is a non-invasive treatment for lymphedema with the
 8 aim to reduce and control the amount of swelling in the affected limb and restore function.
 9 CLT is a noninvasive treatment that is a considered a standard of care for lymphedema.
 10 This method has also been referred to as complete decongestive physiotherapy (CDP), and
 11 complex decongestive therapy (CDT). The treatment aim is to reduce and control the
 12 amount of swelling in the affected limb and restore function. The objective of the technique
 13 is to redirect and enhance the flow of lymph through intact cutaneous lymphatics. Programs
 14 are generally provided on an outpatient basis in the office setting or in a lymphedema
 15 rehabilitation center or clinic (Lasinski and Boris, 2002; MacDonald et al., 2003). The
 16 typical CLT program consists of two phases of treatment: a treatment phase and a
 17 maintenance phase. Phase I, the treatment phase, usually last 2 to 4 weeks. This phase
 18 consists of four components (Lawenda et al., 2009):

- 19 • Skin and nail care: The purpose is to inspect skin, provide moisture and prevent
 20 infection.
- 21 • Manual lymph drainage (MLD): This is a light, massage-like technique that is
 22 performed for 30-60 minutes and is used to stimulate residual lymphatic vessels to
 23 carry excess fluid from the affected extremity.
- 24 • Compression bandaging: This involves wrapping multi-layered bandages around
 25 affected limb.
- 26 • Therapeutic exercise: This includes movement of the limb through a range of
 27 motion with bandaging in place.

28
 29 Most patients will be able to progress to a home-based, self-managed program after an
 30 initial in-office program of 1–2 weeks. Instruction in self-management should begin in the
 31 first week of therapy. Both patients and family are taught bandaging and exercise
 32 techniques, as well as the essentials of skin and nail care. After the initial one- to two-week
 33 program, patients should be re-evaluated to determine whether continued in-office therapy
 34 is necessary or if treatment can be provided in the home.

35
 36 Phase II, the maintenance phase, consists of life-long self-care to maintain the size of the
 37 limb. In this phase, the patient maintains and optimizes the results by applying the
 38 techniques learned in the treatment phase including skin and nail care, wearing an elastic
 39 sleeve during the day, bandaging the affected limb overnight and exercises (Petrek, 2000).

1 **Duration and Frequency**

2 A program of complex lymphedema therapy provided 2–5 times per week for two weeks
3 is generally considered medically necessary for the treatment of primary or secondary
4 lymphedema, in the absence of any contraindications. Programs that go beyond a four-
5 week period are generally considered not medically necessary.

7 **Contraindications**

8 Absolute contraindications to lymphedema therapy include:

- 9 • Acute infections of the affected limb
- 10 • Venous or arterial obstruction (deep vein thrombosis)
- 11 • Active malignancy confirmed or suspected local disease
- 12 • Unwillingness or inability of the member to participate in the treatment

13
14 Relative contraindications to lymphedema therapy include:

- 15 • Suspicion of deep vein thrombosis prior to starting treatment
- 16 • Congestive heart failure
- 17 • When the local massage is performed in area of irradiated soft tissue

18
19 (Note: Placing an acupuncture needle in a limb at risk of, or exhibiting lymphedema is
20 absolutely contraindicated. For more information, see the *Acupuncture Services Medical*
21 *Policy/Guideline (CPG 264 – S)* clinical practice guideline.)

23 **GENERAL BACKGROUND**

24 Lymphedema is defined as the excessive and persistent accumulation of protein rich fluid
25 that collects in the interstitial spaces, due to an inefficiency of the lymphatic system (Szuba
26 et al., 2002; Leal et al., 2009). Lymphedema occurs primarily as a result of malformation,
27 underdevelopment, or acquired disruption of the lymphatic circulation (Szuba et al., 2002).
28 Primary lymphedema is due to congenital defects of the lymphatic system, which can affect
29 from one to as many as four limbs or other parts of the body and is considered rare (National
30 Lymphedema Network, 2011). Secondary lymphedema is acquired and is due to an
31 obstruction or interruption in the lymphatic circulation. Secondary lymphedema can
32 develop as a result of surgery, radiation, infection or trauma. It is a common treatment-
33 related side effect experienced by cancer patients. Patients that undergo surgery for breast
34 cancer that includes node dissection or axillary radiation therapy are at high risk of
35 developing lymphedema.

36
37 Historically, lymphedema has been classified into 3 stages based on its severity and on
38 observation of the patient’s condition. Currently, the International Society of
39 Lymphedema is recognizing a Stage 0 in patients, which refers to a latent or sub-clinical
40 condition where swelling is not evident despite impaired lymph circulation. Patients often
41 report a feeling of heaviness in the limb; however, many patients are asymptomatic in the
42 latency stage. Stage 0 may be present for months or years prior to a patient exhibiting signs

1 and symptoms of edema. Stage I lymphedema is referred to as spontaneously reversible
2 lymphedema (Lawenda et al., 2009; Bicego et al., 2006) and typically involves pitting
3 edema, an increase in limb girth (usually upper extremity), and heaviness. Stage II is also
4 known as spontaneously irreversible lymphedema and it is marked by spongy consistency
5 of the tissue and non-pitting edema (Bicego et al., 2006). Tissue fibrosis marks the
6 beginning of hardening of the limbs and increased girth of extremity and is often found in
7 Stage II (Bicego et al., 2006). Stage III is the most advanced stage and is often referred to
8 as lymphostatic elephantiasis. During Stage III the swelling is irreversible with tissue being
9 fibrotic and unresponsive including patients who present with very large limb(s) size. It is
10 associated with a significant increase in the severity of the fibrotic response, tissue volume,
11 and other skin changes such as papillomas, cysts, fistulas, and hyperkeratosis (Lawenda et
12 al., 2009; Zuther, 2005). With regards to Stage 0, the literature is insufficient to conclude
13 that the use of CDT is either clinically effective or ineffective in the treatment of subclinical
14 or latent stage of breast cancer related lymphedema.

15
16 The best practice or gold standard for lymphedema treatment is considered CDT,
17 also known as complex lymphedema therapy (CLT). CDT is a noninvasive treatment and
18 consists of four basic components as follows: skin and nail care, manual lymph drainage
19 (MLD), followed by bandaging/compression, education, and exercise. The goal of CDT is
20 to reduce and control the amount of swelling in the affected limb and restore function.
21 A treatment option that may be used to manage secondary lymphedema is intermittent
22 pneumatic compressions (IPC) (vasopneumatic compression) which is often added to
23 CDT. However, evidence does not support the addition of IPC to CDT or within any
24 treatment plan. Low-level laser therapy (LLLT) is another treatment option that has
25 been studied as a treatment when used in conjunction with other standard lymphedema
26 treatments. However, low-level laser is currently considered experimental, investigational
27 and/or unproven. Exercise demonstrates improvements in function and quality of life
28 (QoL), but not in limb reduction. The goal of all conservative treatment is to reduce and
29 control the amount of swelling in the affected limb and restore function.

30 31 **DOCUMENTATION GUIDELINES**

32 Documentation should support a diagnosis of lymphedema and not tissue edema due to
33 other etiologies (chronic venous insufficiency, congestive heart failure, acute infection(s),
34 etc.). Recent changes in the patient's condition as well as prior unsuccessful therapies
35 (elevation, bandaging, diuresis, etc.) should be reported to justify the need for skilled
36 services.

37 38 **EVIDENCE REVIEW**

39 Lymphedema is a common sequela of cancer or its treatment that affects the lymphatic
40 transport system that results in failure of lymph node drainage. Secondary lymphedema is
41 often a debilitating, chronic, progressive condition that commonly occurs after treatment
42 of breast cancer. A number of health professional and patient instigated conservative

1 therapies have been developed to help treat this condition. A systematic review
 2 conducted by Moseley et al. (2007) reviewed the common conservative therapies used
 3 for management of secondary arm lymphedema as follows: complex physical
 4 therapy, manual lymphatic drainage, pneumatic pumps, oral pharmaceuticals, low level
 5 laser therapy, compression bandaging and garments, limb exercises and limb
 6 elevation. This study found that the more intensive and health care professional driven
 7 therapies, such as complex physical therapy (skin and nail care, manual lymphatic
 8 drainage, a multilayer compression bandage and therapeutic exercises), manual lymphatic
 9 drainage, pneumatic pump and laser level light therapy generally yielded the greater
 10 volume reductions, compared to self-instigated therapies such as compression garment
 11 wear, exercises and limb elevation. These self-care methods showed reductions, however
 12 in lesser volumes. All conservative therapies reviewed in this study produced
 13 improvements in subjective arm symptoms and QoL issues, where these were measured.

14
 15 Stout et al. (2008) completed a study on Stage 0 lymphedema. They used infrared
 16 optoelectronic technology to identify those at risk for edema based on volume
 17 measurements. This technology allows for changes to be noted before they are actually
 18 visible to the eye. When these changes are noted, treatment initiated immediately may
 19 prevent the development of further stages of lymphedema. However, there is no standard
 20 for the treatment of early-stage, subclinical lymphedema. When the diagnosis of breast
 21 cancer related lymphedema is delayed, therapeutic management requires intensive
 22 decongestive therapy and life-long maintenance. This study suggested that an early
 23 intervention protocol with 20- to 30-mm Hg compression garments, significantly reduced
 24 the affected limb volume to near baseline measures and prevented progression to a more
 25 advanced stage of lymphedema for at least the first year postoperatively. Further research
 26 is warranted to confirm the long-term clinical and cost effectiveness of this early
 27 intervention model compared with a traditional model in treating breast cancer related
 28 lymphedema.

29 30 **Complete Decongestive Therapy (CDT), Manual Lymphatic Drainage (MLD), and** 31 **Compression Methods**

32 A prospective trial of complete decongestive therapy for upper extremity lymphedema after
 33 breast cancer was reviewed by Mondry et al. (2004). Patients completed 2-4 weeks
 34 (median, 2 weeks) of treatment; including skin and nail care, manual lymphatic
 35 drainage, a multilayer compression bandage and therapeutic exercises. Edema of the
 36 affected limb was reassessed on a weekly basis. Authors concluded that decreasing girth
 37 correlated significantly with decreasing visual analogue scale scores for pain, but not
 38 with increasing QoL. Data gathered showed median girth reduced 1.5 cm and median
 39 volume reduced 138mL. This study concluded that compliance with the treatment regimen
 40 at home decreased with duration of the program and girth reductions contributed to less
 41 pain. Increased frequency of treatment sessions provides marked improvement in girth,
 42 volume, and weight but resulted in poorer compliance. Longer latency more

1 successfully reduces girth, volume, and pain and increases QoL. Pain and QoL are
2 improved by treatment and continue to improve after treatment has ended. A randomized
3 controlled trial conducted by McNeely et al. (2004) looked at the addition of manual lymph
4 drainage to compression therapy for managing breast cancer-related lymphedema. The
5 authors of this study compared the reduction in arm lymphedema volume achieved from
6 manual lymph drainage massage in combination with multi-layered compression
7 bandaging to that achieved by compression bandaging alone. Treatment group one
8 received manual lymph drainage (MLD)/compression bandaging (CB). This group
9 received 45 minutes of daily MLD and CB, Monday-Friday for 4 weeks. The second
10 treatment group received short stretch bandaging, Monday-Friday for 4 weeks.
11 Authors concluded that a significant reduction in lymphedema volume was found over the
12 4 week period for both the manual lymph drainage/compression bandaging and
13 compression bandaging alone groups. No significant differences existed between
14 groups (McNeely et al., 2004).

15
16 Koul et al. (2007) assessed the results of combined decongestive therapy and manual
17 lymphatic drainage in patients with breast cancer-related lymphedema over a two-year
18 period. This study was a non-randomized clinical trial that reviewed data from 250 patients
19 with a final analysis reviewed from 138 patients. The pre- and post-treatment volumetric
20 measurements were compared and correlated with age, body mass index, and type of
21 surgery, chemotherapy, and radiotherapy. One group was treated with all 4 parts of
22 combined decongestive therapy for 1 hour daily for up to several weeks, depending on the
23 severity and response. Combined decongestive therapy consisted of manual lymphatic
24 drainage, compression, exercises for the arm and shoulder, and deep breathing to help
25 promote venous and lymphatic flow. Patients were also fitted with custom-made
26 garments to be worn daily while awake and removed at bedtime. Self-lymph drainage at
27 least once daily was also recommended. A second treatment group received MLD alone.
28 They were also fitted for custom compression garments. Self-lymph drainage was also
29 recommended. A third treatment group received one hour of home instruction and
30 counseling, including simple self-drainage techniques, skin care, and exercise. They also
31 received custom compression garments. Results noted a significant reduction in arm
32 volumes at 1 year after the beginning of treatment with some or all components of
33 combined decongestive therapy in patients with lymphedema after breast cancer treatment.

34
35 Patients with moderate to severe lymphedema had a maximal response after combined
36 decongestive therapy, and patients enrolled in the home program had mild lymphedema
37 and less dramatic responses to treatment. Authors concluded that combined
38 decongestive therapy and manual lymphatic drainage with exercises were associated with
39 a significant reduction in the lymphedema volume in all groups assessed. Long-term
40 management of breast cancer-related lymphedema after intensive decongestive therapy
41 was studied by Vignes et al. (2007). The authors' aim was to describe the effect of the
42 maintenance therapy on lymphedema volume reduction and to analyze the impact of the

1 different components of treatment in women with upper limb lymphedema after breast
2 cancer treatment. The treatment consisted of an intensive phase of CDT, including manual
3 lymph drainage (30 minutes, 5 times a week), low stretch compression bandaging (24 hours
4 daily), exercises after bandages were applied to enhance lymphatic flow from peripheral
5 to central compartments and skin care. Maintenance therapy consisted of
6 education (3 bandages per week). Authors concluded that bandaging and elastic
7 sleeves are a key component to maintenance therapy after intensive CDT.

8
9 A systematic review was conducted by Karki et al. (2009) on the effects and harms of
10 physiotherapy methods of lymphedema therapy in breast cancer patients. Fourteen
11 randomized controlled studies were included, two of which had moderate risk of bias and
12 the remainder had high risk. There was moderate evidence that compression bandages
13 alone decreased lymphedema, and that pneumatic pumps had no effect on
14 lymphedema compared to no treatment. With the remainder of the studies that had high
15 risk of bias, the interventions and comparisons varied across all trials. This review found
16 moderate evidence to support that compression bandages decreased lymphedema.
17 There was no evidence regarding volume reduction outcomes in any other body part
18 except the upper limb. Evidence on other physiotherapy methods and combinations is
19 limited due to poor quality of the studies. Devoogdt et al. (2010) conducted a systematic
20 review of combined physical therapy, intermittent compression, and arm elevation for
21 treatment of lymphedema secondary to axillary dissection for breast cancer. The review
22 included ten randomized controlled trials and non-randomized, experimental trials. The
23 review found that combined physical therapy can be considered as an effective treatment
24 modality for treatment of lymphedema; however, the effectiveness of its different
25 components remains uncertain. Szolnoky et al. (2009) compared manual lymphatic
26 drainage with manual lymphatic drainage plus intermittent pneumatic
27 compression for treatment of unilateral arm lymphedema in 27 women previously
28 treated for breast cancer. One treatment group received complex decongestive
29 physiotherapy (CDP), which included manual lymph drainage (MLD) using the Vodder
30 technique. Treatment sessions were for 60 minutes per day for 10 consecutive business
31 days by a specific physiotherapist, followed by skin care, bandaging, and exercise. MLD
32 was performed on the neck, breast, and abdomen. The second treatment group received
33 complex decongestive physiotherapy plus intermittent pneumatic compression
34 (CDP+IPC). This included the same MLD using the Vodder technique for 30 minutes
35 per day for 10 days, followed by 30 minutes of IPC with a Lympha Mat device at a pressure
36 of 50 mmHg. Patient also received skin care, bandaging, and exercise. Each treatment
37 method was effective in reducing limb size, but the combination treatment of
38 CDP+IPC showed statistically significant greater reductions in limb size when compared
39 to CDP alone, with no negative side effects noted. No other statistically significant changes
40 were noted in the patients' subjective reports with either treatment method at any time.

1 A technology assessment requested by Centers for Medicare and Medicaid Services (CMS)
 2 was conducted by McMaster University Evidence-based Practice Center for the Agency
 3 for Healthcare Research and Quality (AHRQ) (Oremus et al., 2010) diagnosis and
 4 treatment of secondary lymphedema. The review included randomized controlled trials or
 5 observation studies with comparison groups (e.g., cohort, case control). The assessment
 6 concluded the following:

- 7 • CDT has been observed to have a significant effect on edema reduction and is
 8 recognized internationally as a successful treatment for lymphedema.
- 9 • There is no single treatment that is considered usual care for lymphedema. At this
 10 time, CDT, which is a combination of therapies, is suggested as the main method
 11 of conservative care for lymphedema. CDT includes manual lymphatic drainage
 12 (MLD), application of compression low stretch bandages, exercise, and skin care.

13
 14 A randomized controlled-group study conducted by Kim et al. (2010) investigated the
 15 differences between the effects of complex decongestive physiotherapy with and without
 16 active resistive exercise for the treatment of patients with breast cancer-related
 17 lymphedema. Treatment group one received CDT (manual lymphatic
 18 drainage, compression therapy, and exercise, including resistance training) 5 times a
 19 week for 2 weeks followed by self-administered treatment for another 6 weeks. The control
 20 group received the CDT without the resistance training added to the exercise program.
 21 Authors concluded that active resistive exercise with CDT did not create additional
 22 swelling and assisted with reduction of arm volume. QoL was also improved for this group.
 23 The National Lymphedema Network (NLN) published a position statement regarding
 24 treatment of lymphedema (2011). Included in the document were the following statements
 25 regarding CDT:

- 26 • CDT is the main treatment for lymphedema. Experts who treat lymphedema
 27 consider CDT the “gold standard” of treatment. The treatment has been shown to
 28 be safe and effective. CDT is the current international standard of care for managing
 29 lymphedema.
- 30 • CDT has been shown to be effective in large numbers of case studies demonstrating
 31 limb volume reductions of 50–70% or more, improved appearance of the limb,
 32 reduced symptoms, improved quality of life, and fewer infections after treatment.
 33 Even people with progressive lymphedema for 30 years or more before starting
 34 CDT have been shown to respond.
- 35 • Patient adherence during Phase II CDT is critical for preserving volume reduction.
- 36 • It is recommended that CDT adaptations or other lymphedema treatments be used
 37 on a case-by-case basis under the supervision of a healthcare provider (e.g.,
 38 physician, nurse, physician assistant, therapist) with demonstrated expertise in
 39 lymphedema management.

40
 41 In 2020, the International Society of Lymphology (ISL) published an updated consensus
 42 document regarding the diagnosis and treatment of peripheral lymphedema. The document

1 makes the following notes regarding lymphedema treatment that was consistent with their
2 2013 consensus statements:

- 3 • CDT is included in the statement as a standard treatment for lymphedema that is
4 backed by longstanding experience. The first phase includes skin care, light manual
5 massage, range of motion exercise and compression with multilayered bandage-
6 wrapping. The second phase aims to conserve and optimize results obtained in
7 Phase 1.
- 8 • An assessment should be made of limb volume before, during and after treatment.
9 Treatment outcomes should be reported in a standardized manner in order to assess
10 effectiveness of treatment protocols.

11
12 Hwang et al. (2013) completed a systematic review and meta-analysis on the effects of
13 MLD on breast cancer-related lymphedema. They investigated whether manual lymphatic
14 drainage (MLD) could prevent or manage limb edema in women after breast-cancer
15 surgery. In total, 10 RCTs with 566 patients were identified. Authors concluded that
16 the current evidence from RCTs does not support the use of MLD in preventing or treating
17 lymphedema. However, clinical and statistical inconsistencies between the various
18 studies confounded our evaluation of the effect of MLD on breast-cancer-related
19 lymphedema. Lasinski (2013) summarized the evidence on the management of lymphedema
20 and provided recommendations. CDT is effective in reducing lymphedema, although the
21 contribution of each individual complete decongestive therapy component has not been
22 determined. In general, levels of evidence for complete decongestive therapy are
23 moderate. Fu et al. (2014) aimed to provide healthcare professionals with evidence-
24 based clinical practice guidelines for lymphedema treatment and management through a
25 systematic review. Findings of the systematic review support complete decongestive therapy,
26 compression bandages, and compression garments with highest evidence for best clinical
27 practice. Weight management, full-body exercise, education, prevention, and early
28 intervention protocols are likely to be effective for clinical practice.

29
30 Shao et al. (2014) sought to determine whether the use of an intermittent pneumatic pump
31 (IPC) could manage lymphedema effectively. Seven randomized controlled trials, with 287
32 patients, were included. Results showed that the use of the IPC could alleviate
33 lymphedema, but no significant difference between routine management of lymphedema
34 with or without pneumatic pump existed. Authors concluded that current trials fail to show
35 the effectiveness of the addition of an IPC to the routine management of BCRL. Leung et
36 al. (2015) evaluated the available evidence for the treatment of secondary lower limb
37 lymphedema in patients with malignancies. Authors concluded that few studies have
38 evaluated the clinical effectiveness and potential side effects of treatments for lower limb
39 lymphedema. Moreover, symptoms and quality-of-life assessments were inconsistently
40 reported. All included studies report lower limb volume reduction after treatment, which
41 includes complex decongestion therapy, graded compression stockings and lymphovenous
42 microsurgical shunts. Adequately powered randomized controlled trials of these

1 interventions are recommended. Ezzo et al. (2015) assessed the efficacy and safety of MLD
2 in treating BCRL. Six trials were included. Authors concluded that MLD is safe and
3 may offer additional benefit to compression bandaging for swelling reduction.
4 Compared to individuals with moderate-to-severe BCRL, those with mild-to-
5 moderate BCRL may be the ones who benefit from adding MLD to an intensive
6 course of treatment with compression bandaging. This finding, however, needs to be
7 confirmed by randomized data. In trials where MLD and sleeve were compared with a non-
8 MLD treatment and sleeve, volumetric outcomes were inconsistent within the same trial.
9 Findings were contradictory for function (range of motion), and inconclusive for quality of
10 life. For symptoms such as pain and heaviness, 60% to 80% of participants reported feeling
11 better regardless of which treatment they received. One-year follow-up suggests that once
12 swelling had been reduced, participants were likely to keep their swelling down if they
13 continued to use a custom-made sleeve. Finnane et al. (2015) sought to summarize efficacy
14 findings of reviews on lymphedema treatment. Overall, there was wide variation in review
15 methods. The quality of studies included in reviews, in study design and reporting
16 overall, has been poor. Reviews consistently concluded that complex physical therapy is
17 effective at reducing limb volume. Volume reductions were also reported after the use of
18 compression garments, pumps, and manual lymphatic drainage. However, greatest
19 improvements were reported when these treatments formed a combined treatment
20 program. Large, well-designed, evaluated, and reported randomized, controlled trials are
21 needed to evaluate and compare treatments.

22
23 Elastic therapeutic taping (e.g., Kinesio taping) has been proposed as a treatment
24 intervention for lymphedema, given its properties and hypothesized mechanism to lift the
25 skin away from the adjacent muscle and allow intercellular fluid to flow more freely. For
26 example, lymph will move more easily out of lymph channels and into larger lymph ducts
27 for uptake. Bialoszewski et al. (2009) studied the effects of KT in reducing edema of lower
28 limbs in patients subjected to limb lengthening. Twenty-four patients developed post-
29 surgical lymphedema. They were randomized into 2 groups. One group received taping
30 and the other received standard physiotherapy (lymphatic drainage). Both methods reduced
31 edema significantly pre- and post-treatment (after 10 days); however, the application of the
32 KT produced a significantly faster reduction of edema compared to standard lymphatic
33 drainage methods. A study by Tsai et al. (2009) hypothesized whether KT could replace
34 the bandage in decongestive lymphatic therapy (DLT) for breast-cancer-related
35 lymphedema. The pilot study looked at standard DLT combined with pneumatic
36 compression (PC) or modified DLT using KT combined with PC; both types of treatments
37 resulted in reduced girth measurements of the upper extremity and other outcomes in 41
38 patients with breast-cancer-related lymphedema. Results demonstrated no significant
39 differences between the two types of treatments. Thus, use of KT could replace the bandage
40 typically used in DLT. Morris et al. (2013) reported on a systematic review with the
41 purpose of this study was to investigate the effect of Kinesio Tex tape (KTT) from
42 randomized controlled trials (RCTs) in the management of clinical conditions. The review

1 included 8 RCTs: 6 included patients with musculoskeletal conditions; 1 with breast-
 2 cancer-related lymphedema; and 1 included stroke patients with muscle spasticity. Six
 3 studies included a sham or usual care tape/bandage group. The review found limited to
 4 moderate evidence that KTT is no more clinically effective than sham or usual care
 5 tape/bandage. The authors concluded that there currently exists insufficient evidence to
 6 support the use of KTT over other modalities in clinical practice. Kalron and Bar-Sela
 7 (2013) reported on a systematic review that assessed the effects of therapeutic Kinesio
 8 Taping (KT) on pain and disability in participants suffering from musculoskeletal,
 9 neurological, and lymphatic pathologies. Twelve met inclusion criteria. The final 12
 10 articles were subdivided according to the basic pathological disorders: musculoskeletal
 11 ($N=9$) (4 randomized, controlled trials (RCT), 3 single-blinded RCT, 1 cross-over trial and
 12 one case-control study); neurological ($N=1$) (RCT); and lymphatic ($N=2$) (RCT).
 13 Regarding lymphatic disorders, inconclusive evidence was reported. The authors
 14 concluded that although KT has been shown to be effective in aiding short-term pain, there
 15 is no firm evidence-based conclusion of the effectiveness of this application on the majority
 16 of movement disorders within a wide range of pathologic disabilities. Gatt et al. (2017)
 17 aimed to determine the effectiveness and safety of kinesiotope (KT) in the management
 18 of cancer-related lymphedema (CRL) compared to compression bandaging or hosiery. Five
 19 studies were included in the meta-analysis of the primary outcome limb volume ($n = 203$,
 20 KT $n = 91$, compression $n = 112$). No significant difference existed between the
 21 interventions. An increased risk of skin complications with KT was reported in five studies
 22 affecting between 10% and 21% of patients. Where lymphedema-related symptoms were
 23 reported KT was found to be superior to compression. Paradoxically, patients
 24 receiving bandaging reported a higher QoL. Thus, authors concluded that KT was
 25 not found to be more comfortable than bandaging and should only be used with caution
 26 where bandaging cannot be used.

27
 28 Torres-Lacombe et al. (2020) compared the effects of four types of bandages and kinesio-
 29 tape and determine which one is the most effective in women with unilateral breast cancer-
 30 related lymphedema. A total of 150 women presenting breast-cancer-related lymphedema
 31 were randomized into five groups ($n = 30$). All women received an intensive phase of
 32 complex decongestive physiotherapy including manual lymphatic drainage, pneumatic
 33 compression therapy, therapeutic education, active therapeutic exercise, and bandaging.
 34 The only difference between the groups was the bandage or tape applied (multilayer;
 35 simplified multilayer; cohesive; adhesive; kinesio-tape). The main outcome was
 36 percentage excess volume change. Other outcomes measured were heaviness and tightness
 37 symptoms, and bandage or tape perceived comfort. Data were collected at baseline and
 38 finishing interventions. This study showed significant differences between the bandage
 39 groups in absolute value of excess volume. The five groups exhibited a significant decrease
 40 in symptoms after interventions, with no differences between groups. In addition, kinesio-
 41 tape was perceived as the most comfortable by women and multilayer as the most
 42 uncomfortable ($P < 0.001$). The most effective were the simplified multilayer and the

1 cohesive bandages. The bandages/tape with the least difference were kinesio- and adhesive
2 bandage.

3
4 Zasadzka et al. (2018) compared the effectiveness of multi-layer compression
5 bandaging (MCB) and CDT for treating lymphedema in elderly patients. One
6 hundred three patients (85 women and 18 men) aged ≥ 60 years, with unilateral lower
7 limb lymphedema. The subjects were divided into two groups: 50 treated with CDT
8 and 53 with MCB. Pre- and post-treatment BMI, and average and maximum
9 circumference of the edematous extremities were analyzed. Results noted a reduction
10 in swelling in both groups was achieved after 15 interventions. Both therapies
11 demonstrated similar efficacy in reducing limb volume and circumference, but MCB
12 showed greater efficacy in reducing the maximum circumference. Authors concluded
13 that compression bandaging is a vital component of CDT. Maximum lymphedema
14 reduction during therapy and maintaining its effect cannot be achieved without it.
15 Sezgin Ozcan et al. (2018) evaluated the effects of CDT on upper extremity
16 functions, the severity of pain, and quality of life. A total of 37 women with breast
17 cancer-related lymphedema (BCRL) [age, 53.6 ± 11.2 (28-72)] were included in this
18 study. All patients underwent CDT-phase 1 program, including meticulous skin care,
19 manual lymphatic drainage, remedial exercises, and compression bandages. The
20 mean of the posttreatment volume of the affected limb was lower compared to
21 pretreatment volume. A statistically significant reduction in pain and heaviness VAS
22 scores and improvement of shoulder mobility among upper extremities with
23 lymphedema ($p < 0.001$) was noted after CDT. The mean of posttreatment DASH
24 score was lower, and all subgroups of the SF-36 parameters were increased after the
25 CDT application. Also, being under 65 years old, having a body mass index above
26 30 and short duration of lymphedema were found to be related to greater
27 improvement in upper extremity functions. Authors concluded that CDT provides
28 enhancement of upper extremity functions and quality of life in patients with BCRL.

29
30 Michopoulos et al. (2020) evaluated the effectiveness and safety of CDT of phase I in the
31 Greek population with lymphedema. CDT was implemented in all patients for 20 sessions
32 in a 4-week treatment period. The edema's (excess volume (EV) and percent of excess
33 volume (PEV)) measurements were carried out four times in the treatment period, whereas
34 the percent reduction of excess volume (PREV) was calculated at the end of phase I. Every
35 infection, trauma of skin, and pain of limb during the treatment was also recorded. One-
36 hundred five patients with lymphedema were enrolled, of whom 31.4% had upper limb
37 lymphedema and 68.6% had lower limb lymphedema. A significant reduction between the
38 pre-treatment and post-treatment values of EV and PEV was found for both upper and
39 lower limb lymphedema. For patients with upper limb lymphedema, the average PREV
40 was 66.5%, whereas for patients with lower limb lymphedema, a 71.5% median value was
41 measured. No side effects from the treatment were recorded during CDT. Authors

1 concluded that the proper treatment of the CDT phase I ensures safety and a great reduction
2 in edema in patients with lymphedema that predispose the success of phase II of CDT.

3
4 Watanabe et al. (2020) authored an article on the development and themes of diagnostic
5 and treatment procedures for secondary leg lymphedema in patients with gynecologic
6 cancers. They note that for the treatment of lymphedema, complex decongestive
7 physiotherapy (CDP) including manual lymphatic drainage (MLD), compression therapy,
8 exercise, and skin care, are generally performed. In recent years, CDP has often required
9 effective multi-layer lymph edema bandaging (MLLB) or advanced pneumatic
10 compression devices (APCDs). If CDP is not effective, microsurgical procedures can be
11 performed. They conclude that the most important concern is the prevention of secondary
12 lymphedema, which is achieved through approaches such as skin care, weight control,
13 gentle limb exercises, avoiding sun and heat, and elevation of the affected leg.

14
15 In accordance with the most recent Consensus Document of the International Society of
16 Lymphology (2020), CDT should include two phases: 1. Phase I: characterized by skincare,
17 manual lymphatic drainage (MLD), with or without deeper techniques including muscle
18 pumping exercises or hydraulic pressotherapy, followed by multilayer compression
19 bandage, aiming at improving lymphedema volume; 2. Phase II: characterized by skincare
20 and compression garments wearing, including lowstretch elastic stocking or sleeve, aiming
21 at avoiding complications and conserving the results obtained in Phase I.

22
23 Thompson et al. (2021) evaluated the effectiveness of MLD for those at-risk of or living
24 with lymphedema. Seventeen studies with a total of 867 female and two male participants
25 were included. Only studies examining breast cancer-related lymphedema were identified.
26 Some studies reported positive effects of MLD on volume reduction, quality of life and
27 symptom-related outcomes compared with other treatments, while other studies reported
28 no additional benefit of MLD as a component of complex decongestive therapy. In patients
29 at-risk, MLD was reported to reduce incidence of lymphedema in some studies, while
30 others reported no such benefits. Authors concluded that reviewed articles reported
31 conflicting findings and were often limited by methodological issues. They suggest the
32 need for further experimental studies on the effectiveness of MLD in lymphedema. There
33 is some evidence that MLD in early stages following breast cancer surgery may help
34 prevent progression to clinical lymphedema. MLD may also provide additional benefits in
35 volume reduction for mild lymphedema. However, in moderate to severe lymphedema,
36 MLD may not provide additional benefit when combined with complex decongestive
37 therapy.

38
39 Kalemikerakis et al. (2021) authored an article on the diagnosis and management of cancer-
40 related lymphedema. They note that early diagnosis and treatment of lymphedema is
41 related with better therapeutic outcomes. Women with breast cancer confront more
42 problems with lymphedema than with mastectomy. Its effect on patients' quality of life is

1 relevant to changes in body image, self-esteem, feelings of weakness, fear and anxiety
2 about disease progression, financial costs, and reduced limb function. Relative to
3 conservative management, authors summarize that CDT remains the treatment of choice
4 and in combination with exercise, weight control programs and self-care training seems to
5 significantly improve patients' quality of life. Forner-Cordero et al. (2021) assessed
6 whether treatment with intermittent pneumatic compression plus multilayer bandages is
7 not inferior to classical trimodal therapy with manual lymphatic drainage in the
8 decongestive lymphedema treatment. 194 lymphedema patients, stage II-III with excess
9 volume > 10% were stratified within upper and lower limb and then randomized to one of
10 the three treatment groups. Baseline characteristics were comparable between the groups.
11 For interventions all patients were prescribed 20 sessions of the following regimens: Group
12 A (control group): manual lymphatic drainage + Intermittent Pneumatic Compression +
13 Bandages; Group B: pneumatic lymphatic drainage + Intermittent Pneumatic Compression
14 + Bandages; and Group C: only Intermittent Pneumatic Compression + Bandages. The
15 outcome was the percentage reduction in excess volume (PREV). Results demonstrated
16 that all patients improved after treatment. Global mean of PREV was 63.9%, without
17 significant differences between the groups. Most frequent adverse events were discomfort
18 and lymphangitis, without differences between groups. A greater baseline edema, an upper-
19 limb lymphedema and a history of dermatolymphangitis were independent predictive
20 factors of worse response in the multivariate analysis. Authors concluded that decongestive
21 lymphatic therapy performed only with intermittent pneumatic compression plus bandages
22 is not inferior to the traditional trimodal therapy with manual lymphatic drainage. This
23 approach did not increase adverse events.

24
25 McNeely et al. (2022) examined the efficacy of nighttime compression as a self-
26 management strategy for women with chronic breast cancer-related lymphedema. Authors
27 conducted a parallel 3-arm, multicenter, randomized trial. Women were recruited from 3
28 centers in Canada and randomized to group 1 (daytime compression garment alone
29 [standard care]), group 2 (daytime compression garment plus nighttime compression
30 bandaging), or group 3 (daytime compression garment plus the use of a nighttime
31 compression system garment). The primary outcome was the change in excess arm volume
32 from the baseline to 12 weeks. Participants from all groups used a nighttime compression
33 system garment from weeks 13 to 24. One hundred twenty women were enrolled, 118
34 completed the randomized trial, and 114 completed the 24-week follow-up. The rates of
35 adherence to nighttime compression were $95\% \pm 15\%$ and $96\% \pm 11\%$ in the compression
36 bandaging and nighttime compression system groups, respectively. After the intervention,
37 the addition of nighttime compression was found to be superior to standard care for both
38 absolute milliliter reductions ($P = .006$) and percentage reductions ($P = .002$) in excess arm
39 lymphedema volume. Significant within-group changes were seen for quality of life across
40 all groups; however, no between-group differences were found ($P > .05$). Authors
41 concluded that this study demonstrated a significant improvement in arm lymphedema

1 volume from the addition of nighttime compression whether through the application of
 2 compression bandaging or through the use of a nighttime compression system garment.

3
 4 De Vrieze et al. (2022) investigated the effect of fluoroscopy-guided manual lymphatic
 5 drainage (MLD) versus traditional MLD or placebo MLD for the treatment of breast
 6 cancer-related lymphedema (BCRL) when added to decongestive lymphatic therapy
 7 (DLT). All participants received standard DLT (education, skin care, compression therapy
 8 and exercises). Participants were randomized to also receive fluoroscopy guided MLD
 9 ($n = 65$), traditional MLD ($n = 64$) or placebo MLD ($n = 65$). Participants received
 10 14 sessions of physiotherapy during the 3-week intensive phase and 17 sessions during the
 11 6-month maintenance phase. Participants performed self-management on the other days.
 12 All outcomes were measured: at baseline; after the intensive phase; after 1, 3 and 6 months
 13 of maintenance phase; and after 6 months of follow-up. The primary outcomes were
 14 reduction in excess volume of the arm/hand and accumulation of excess volume at the
 15 shoulder/trunk, with the end of the intensive phase as the primary endpoint. Excess
 16 lymphedema volume decreased after 3 weeks of intensive treatment in each group. The
 17 effect of fluoroscopy guided MLD was very similar to traditional MLD and placebo MLD.
 18 Authors concluded that in patients with chronic BCRL, MLD did not provide clinically
 19 important additional benefit when added to other components of DLT.

20
 21 Borman et al. (2022) evaluated the effects of CDT in patients with breast cancer-related
 22 lymphedema (BCRL), in regard to volume reduction, functional status and QoL. Fifty
 23 patients with unilateral BCRL were included. All patients received combined phase 1 CDT
 24 including skincare, manual lymphatic drainage, multilayer bandaging, and supervised
 25 exercises, 5 times a week for 3 weeks, as a total of 15 sessions. Patients were assessed by
 26 limb volumes and excess volumes. The functional disability was evaluated by quick
 27 disability of arm, shoulder, and hand questionnaire (Q-DASH). QoL was assessed by the
 28 European Organization for Research and Treatment of Cancer Core Cancer Quality of Life
 29 Questionnaire (EORTC QLQ-C30) and its breast-cancer-module (EORTC QLQ-BR23).
 30 Fifty females with mean age of 53.22 ± 11.2 years were included. The median duration of
 31 lymphedema was 12 months. There were 22 patients in stage1, 26 in stage2 and 2 patients
 32 in stage3. The mean baseline limb and excess volumes were significantly decreased at the
 33 end of therapies. The Q-DASH and EORTC QLQ-C30 and BR23 scores were also
 34 decreased significantly. The improvements in volumes were related negatively with the
 35 duration of lymphedema, and the stage of lymphedema. Authors concluded that CDT in a
 36 combined manner performed daily for 3 weeks, greatly reduces the volumes as well as
 37 improves the disability and QoL, especially when performed earlier.

38
 39 de Sire et al. (2022) completed a review to characterize the comprehensive management of
 40 lymphedema, providing a broad overview of the potential therapy available in the current
 41 literature. They conclude that a multidisciplinary treatment should be truly integrated for
 42 lymphedema patients, and rehabilitation should be considered the cornerstone of the

1 multidisciplinary treatment not only for patients not suitable for surgical interventions but
2 also before and after surgical procedures. Rehabilitation should include (CDT), which
3 includes manual lymph drainage (MLD), skin care, specialized exercises, compression
4 garments and self-education. Rangon et al. (2022) investigated the immediate, short-term,
5 and long-term effects of complex physical therapy and multimodal approaches on
6 lymphedema secondary to breast cancer. Fourteen studies were identified for the
7 systematic review and 11 studies for the meta-analysis. The common outcomes involved
8 total volume, pain, and physical function of the upper limb. Complex physical therapy has
9 shown a favorable tendency to control outcomes in the short- and long-term. The meta-
10 analysis indicated a small effect for volume reduction and a moderate effect for short-term
11 pain reduction. Authors concluded that high-quality evidence suggests a more significant
12 effect of complex physical therapy on multimodal approaches to the control of the upper
13 limb total volume, substantiating the absence of changes in the current clinical practice in
14 the management of lymphedema secondary to breast cancer. Future research should aim to
15 identify concrete effect of therapeutic modalities in the immediate-, short-, and long-term.

16
17 Lin et al. (2022) analyzed the effectiveness of manual lymphatic drainage (MLD) in breast
18 cancer-related lymphedema (BCRL) patients in a systematic review and meta-analysis. In
19 total, 11 RCTs involving 1,564 patients were included, in which 10 trials were deemed
20 viable for inclusion in the meta-analysis. Due to the effects of MLD for BCRL, statistically
21 significant improvements were found on the incidence of lymphedema and pain intensity.
22 Besides, the meta-analysis carried out implied that the effects that MLD had on volumetric
23 changes of lymphedema and quality of life, were not statistically significant. The current
24 evidence based on the RCTs shows that pain of BCRL patients undergoing MLD is
25 significantly improved, while our findings do not support the use of MLD in improving
26 volumetric of lymphedema and quality of life. Torgbenu et al. (2023) aimed to describe
27 and compare international guidelines on lymphedema diagnosis, assessment, and
28 management. This systematic review of 1,564 articles and 159 web pages yielded 14
29 guidelines. All guidelines were from high-income countries. Ten focused exclusively on
30 lymphedema, and four on cancer. Most (n = 13) guidelines recommended an integrated
31 medical, psychological assessment, and physical examination, with a limb volume
32 measurement of >10% in the affected limb compared, confirming a lymphedema diagnosis.
33 Recommended management involved Complex Decongestive Therapy (CDT) followed by
34 self-management using skincare, self-lymphatic drainage massage, exercise, and
35 compression.

36
37 Qiao et al. (2023) analyzed the efficacy of MLD for BCRL. A total of 457 patients were
38 included in the analysis. There was no significant difference in the amount of upper
39 extremity edema between the MLD treatment and control or no MLD groups. However,
40 when the treatment course was ≥ 20 sessions, there was a significant reduction in the upper
41 extremity volume. There was also a significant reduction in the upper extremity volume
42 when treatment duration was >2 weeks. Authors concluded that manual lymphatic drainage

1 treatment statistically did not reduce the upper extremity limb volume of BCRL, but upper
2 extremity volume was reduced at statistically significant levels when treatment number
3 were ≥ 20 sessions or the duration of treatment was >2 weeks.

4
5 Donahue et al. (2023) summarized current BCRL prevention and treatment strategies. They
6 report that complete decongestive therapy (CDT) remains the standard of care for patients
7 with BCRL. Intermittent pneumatic compression, nonpneumatic active compression
8 devices, and low-level laser therapy appear promising in lymphedema management.
9 Currently, no pharmacological approaches have proven successful. Senger et al. (2023)
10 summarized current concepts in primary lymphedema. Primary lymphedema is a
11 heterogeneous group of conditions encompassing all lymphatic anomalies that result in
12 lymphatic swelling. Primary lymphedema can be difficult to diagnose, and diagnosis is
13 often delayed. As opposed to secondary lymphedema, primary lymphedema has an
14 unpredictable disease course, often progressing more slowly. Primary lymphedema can be
15 associated with various genetic syndromes or can be idiopathic. Diagnosis is often clinical,
16 although imaging can be a helpful adjunct. The literature on treating primary lymphedema
17 is limited, and treatment algorithms are largely based on practice patterns for secondary
18 lymphedema. The mainstay of treatment focuses on complete decongestive therapy,
19 including manual lymphatic drainage and compression therapy. For those who fail
20 conservative treatment, surgical treatment can be an option. Microsurgical techniques have
21 shown promise in primary lymphedema, with both lymphovenous bypass and vascularized
22 lymph node transfers demonstrating improved clinical outcomes in a few studies.

23
24 Marotta et al. (2023) aimed to assess the role of KT among the CDT to treat BCRL.
25 Rehabilitation has a key role in the comprehensive management of this condition with
26 several studies reporting positive results after performing complex decongestive therapies
27 (CDT) in women. Kinesio taping (KT) is a rather recent therapeutic approach to treat
28 BCRL, however, evidence in literature regarding its effectiveness is far from being fully
29 characterized. Out of the documents identified, 123 were eligible for data screening, and
30 only 7 RCTs satisfied the eligibility criteria and were included. Authors found that KT
31 might have a positive effect on limb volume reduction in patients with BCRL, studies are
32 of low quality. Authors concluded that this systematic review showed that KT did not
33 significantly reduce the upper limb volume in BCRL women, though it seemed to increase
34 the flow rate during the passive exercise. Further high-quality-studies are needed to
35 improve the knowledge to include KT into a multidisciplinary rehabilitative approach for
36 the management of BC survivors affected by lymphedema.

37
38 Cheng et al. (2023) identified and appraised the current evidence for rehabilitation
39 interventions in HNCaL. Of 1642 citations identified, 23 studies (1.4%; $n = 2147$ patients)
40 were eligible for inclusion. Six studies (26.1%) were randomized clinical trials (RCTs) and
41 17 (73.9%) were observational studies. Five of the 6 RCTs were published during 2020 to
42 2022. Most studies had fewer than 50 participants (5 of 6 RCTs; 13 of 17 observational

1 studies). Studies were categorized by intervention type, including standard lymphedema
 2 therapy (11 studies [47.8%]) and adjunct therapy (12 studies [52.2%]). Lymphedema
 3 therapy interventions included standard complete decongestive therapy (CDT) (2 RCTs, 5
 4 observational studies), modified CDT (3 observational studies), therapy setting (1 RCT, 2
 5 observational studies), adherence (2 observational studies), early manual lymphatic
 6 drainage (1 RCT), and inclusion of focused exercise (1 RCT). Adjunct therapy
 7 interventions included advanced pneumatic compression devices (APCDs) (1 RCT, 5
 8 observational studies), Kinesio Taping® (1 RCT), photobiomodulation (1 observational
 9 study), acupuncture/moxibustion (1 observational study), and sodium selenite (1 RCT, 2
 10 observational studies). Serious adverse events were either not found (9 [39.1%]) or not
 11 reported (14 [60.9%]). Low-quality evidence suggested the benefit of standard
 12 lymphedema therapy, particularly in the outpatient setting and with at least partial
 13 adherence. High-quality evidence was found for adjunct therapy with Kinesio Taping®.
 14 Low-quality evidence also suggested that APCDs may be beneficial.

15 **Other Treatments**

16 **Low Level Laser Therapy (LLLT)**

17 Carati et al. (2003) performed a double blind, placebo controlled randomized, single
 18 crossover trial use of low-level laser therapy (LLLT) for a treatment option for patients
 19 with post mastectomy lymphedema (PML). Participants received either one cycle or two
 20 cycles of LLLT to the axillary region of their affected arm. The authors monitored for
 21 reduction in affected limb volume, upper body extracellular tissue fluid distribution, dermal
 22 tonometry and range of motion. The result yielded two cycles of LLLT improved
 23 lymphedema; however, limb volume reduction was not immediate and was reported 2-3
 24 months post-treatment (Carati et al., 2003). A study conducted by Dirican et al. (2011)
 25 reviewed the authors' short-term experience with low-level laser therapy in the treatment
 26 of breast-cancer related lymphedema. Treatment consisted of laser therapy using 300mJ
 27 for one minute to 17 different points on the surgical scar tissue of the axilla. Patients
 28 were also treated with compression garments or bandaging. Two of the patients
 29 in the study also had sessions using an intermittent compression device. Authors
 30 concluded that patients with breast cancer gain additional benefits in the form of volume
 31 reduction from low level laser therapy when used in conjunction with other standard
 32 treatments (Dirican et al., 2011). Further studies are needed to confirm these findings. Smoot
 33 et al. (2015) examined the literature on effectiveness of LLLT in reducing limb volume and
 34 pain in adults with breast cancer related lymphedema (BCRL). They concluded that moderate
 35 strength evidence supports LLLT in the management of BCRL. The overall review of
 36 literature investigated conservative therapies for secondary arm lymphedema that can be
 37 divided into intensive treatments administered by trained healthcare professionals and limb
 38 maintenance that are carried out by the patient. Treatments that are predominantly
 39 administered by healthcare professionals, such as CDT, MLD, and pneumatic pump
 40 therapy generally yielded the larger reduction in limb volume. LLLT may be a potential
 41 treatment option, but more well-designed studies are needed. Maintenance therapies
 42

1 generally carried out by the patient in a self-care program (e.g., wearing compression
2 garments, performing limb exercises, limb elevation, and self-massage) yielded smaller
3 limb reduction.

4
5 Kozanoglu et al. (2022) investigated the long-term effectiveness of combined intermittent
6 pneumatic compression (IPC) plus low-level laser therapy (LLLT) versus IPC therapy
7 alone in patients with postmastectomy upper limb lymphedema (PML). The patients were
8 allocated into two groups in this single-blinded, controlled clinical trial. Group I received
9 combined treatment with IPC plus LLLT ($n = 21$) and group II received only IPC ($n = 21$).
10 IPC treatment was given 5 sessions per week for 4 weeks (20 sessions). LLLT was also
11 performed 5 sessions per week for 4 weeks (20 sessions). Clinical evaluations were
12 performed before and after the treatment at the 3, 6, and 12-month follow-up visits.
13 According to within-group analysis, statistically significant improvements in the
14 circumference difference and grip strength were observed in both groups. Visual analog
15 scale values for arm pain and shoulder pain during motion were decreased only in group I.
16 Authors concluded that interventions have positive effects on lymphedema, grip strength,
17 and pain. Long-term effects of combined therapy, especially on pain, are slightly superior
18 to the pneumatic compression alone.

19
20 Wang et al. (2022) analyzed the evidence from existing systematic reviews investigating
21 the effectiveness and safety of low-level laser therapy (LLLT) in patients with breast
22 cancer-related lymphedema (BCRL). Conflicting results regarding the effectiveness of
23 LLLT were presented by the overview of systematic reviews. The AMSTAR 2 showed that
24 the methodological quality of included systematic reviews was low or critically low quality
25 due to one or more critical weaknesses. The GRADE and GRADE-CERQual showed that
26 the evidence quality was low to very low for most outcomes. The updated systematic
27 review showed that LLLT may offer additional benefits as compared to compression
28 therapies (pneumatic compression or compression bandage), placebo laser, or no treatment
29 for patients with BCRL. However, when compared to other types of active interventions,
30 LLLT did not improve outcomes significantly. None of the treatment-related adverse event
31 was reported. Many trials had a high or unclear risk of bias for two or more items, and this
32 updated systematic review showed low quality of evidence per outcome using GRADE
33 approach. Due to insufficient data and poor quality of evidence, there is uncertain evidence
34 to reach these conclusions that LLLT is superior to another active or negative intervention
35 and is safe. More RCTs of high methodological quality, with large sample sizes and long-
36 term follow-up, are needed to inform clinical guidelines and routine practice.

37
38 Chiu et a. (2023) aimed to organize existing research and determine the optimal
39 combination of LLLT parameters for BCRL treatment in a meta-analysis. Although low-
40 level laser therapy (LLLT) has been explored as a treatment option for BCRL, they could
41 not find a regimen that is more effective than others, which prompted their study. Authors
42 focused on the aspects of the treatment area, treatment regimen, and total treatment sessions

1 across the included studies. The comparisons between LLLT and non-LLLT were
 2 performed through a meta-analysis. Post-treatment QOL was significantly better in the
 3 axillary group. The group treated "three times/week with a laser density of 1.5-2 J/cm²"
 4 had significantly better outcomes in terms of swelling reduction, both immediately post-
 5 treatment and at 1-3 months follow-ups. The group with > 15 treatment sessions had
 6 significantly better post-treatment outcomes regarding reduced swelling and improved grip
 7 strength. According to these results, LLLT can relieve the symptoms of BCRL by reducing
 8 limb swelling and improving QOL. Further exploration found that a treatment approach
 9 targeting the axilla, combined with an increased treatment frequency, appropriate laser
 10 density, and extended treatment course, yielded better outcomes. However, further
 11 rigorous, large-scale studies, including long-term follow-up, are needed to substantiate this
 12 regimen.

13 14 **Exercise**

15 Kwan et al. (2011) conducted a systematic review of the contemporary literature to distill
 16 the weight of the evidence and provide recommendations for exercise and lymphedema
 17 care in breast cancer survivors. Seven studies were identified addressing resistance
 18 exercise, seven studies on aerobic and resistance exercise, and five studies on other exercise
 19 modalities. Studies concluded that slowly progressive exercise of varying modalities is not
 20 associated with the development or exacerbation of breast cancer-related lymphedema and
 21 can be safely pursued with proper supervision. Combined aerobic and resistance exercise
 22 appear safe, but confirmation requires larger and more rigorous studies. Authors concluded
 23 that strong evidence is now available on the safety of resistance exercise without an
 24 increase in risk of lymphedema for breast cancer patients. Buchan et al. (2016) compared
 25 the effect of progressive resistance- or aerobic-based exercise on breast cancer-related
 26 lymphedema extent and severity, as well as participants' muscular strength and endurance,
 27 aerobic fitness, body composition, upper-body function and QoL. Authors concluded that
 28 participating in resistance- or aerobic-based exercise did not change lymphedema status
 29 but led to clinically relevant improvements in function and QoL, with findings suggesting
 30 that neither mode is superior with respect to lymphedema impact. As such, personal
 31 preferences, survivorship concerns and functional needs are important and
 32 relevant considerations when prescribing exercise mode to those with secondary
 33 lymphedema.

34
 35 Overall, the consensus of managing lymphedema includes an appropriate diagnosis based
 36 on the patient's history and physical examination and a determination that there
 37 is consistent evidence to indicate that lymphedema can be reliably measured
 38 using circumferential measures or volume displacement. Complex decongestive
 39 therapy is suggested as the main method of conservative care for lymphedema and is a
 40 combination of therapies that includes manual lymphatic drainage (MLD), application of
 41 compression low stretch bandages, skin care, education, and exercise. Johansson et al.
 42 (2015) reported on the evidence-based or traditional treatment of cancer-related

1 lymphedema. Authors concluded that with accumulating evidence and experience, it is
2 time to consider if altering these treatment principles is needed. Based on accumulating
3 evidence, authors suggest less emphasis on manual lymph drainage and more on early
4 diagnosis, compression, weight control and exercise for improvement of strength and
5 circulation. Bakar and Tuğral (2017) reviewed the current management strategies for lower
6 extremity management of lymphedema after gynecologic cancer surgery. Studies indicated
7 that the incidence of lower extremity lymphedema ranges between 2.4% and 41% after
8 pelvic lymph node dissection in patients with gynecologic malignancies. Thus,
9 management of lower extremity lymphedema in patients after gynecologic cancer surgery
10 is an important issue. Complex decongestive therapy method is still the gold standard of
11 lymphedema management.

12
13 Nelson (2017) summarizes the results of recent randomized controlled trials (RCTs)
14 investigating the effect of resistance exercise in those with, or at risk for, BCRL. He also
15 wanted to determine whether breast cancer survivors can perform RET at sufficient
16 intensities to elicit gains in strength without causing BCRL flare-up or incidence. A total
17 of 6 RCTs, involving 805 breast cancer survivors, met the inclusion criteria and
18 corresponded to the aims of this review. The results of this review indicated that breast
19 cancer survivors can perform RET at high-enough intensities to elicit strength gains
20 without triggering changes to lymphedema status. There is strong evidence indicating that
21 RET produces significant gains in muscular strength without provoking BCRL. Do et al.
22 (2017) investigated the effects of a complex rehabilitation (CR) program and complex
23 decongestive therapy (CDT) on edema status, physical function, and quality of life in
24 patients with unilateral lower-limb lymphedema after gynecologic cancer surgery. CR
25 comprised of stretching, strengthening, and aerobic exercises was performed for 40min,
26 five times a week for 4weeks. Intensive CDT was administered by a physical therapist
27 during weeks 0-2 and by the patients themselves during weeks 2-4. Results demonstrated
28 that the edema status, fatigue, pain, and GCLQ-K scores were significantly improved in
29 both groups after the 4-week intervention. Physical function and fatigue and the 30-s chair
30 stand test and quadriceps muscle strength were significantly improved in the CRCDT
31 group compared with the CDT alone group. Authors concluded that CR improves physical
32 function, fatigue, and muscular strength without increasing edema status in patients with
33 unilateral lower-limb lymphedema after gynecologic cancer surgery. Yeung et al. (2018)
34 conducted a systematic review and meta-analysis on aquatic therapy compared to other
35 lymphedema interventions. Four RCTs of moderate quality were included. There was
36 moderate level evidence of no significant short-term differences in lymphedema status
37 (relative volume) between patients receiving aquatic lymphatic therapy compared to land
38 based standard care. There was low level evidence that no significant difference between
39 aquatic lymphatic therapy and standard care for improving upper limb physical function.
40 Authors conclude that current evidence indicates no significant benefit of aquatic
41 lymphatic therapy over standard land-based care for treatment of lymphedema. Further
42 research is needed to strengthen the evidence.

1 Baumann et al. (2018) assessed the effect of different types of exercise on breast cancer-
2 related lymphedema (BCRL) in order to understand the role of exercise in this patient
3 group. Eleven randomized controlled trials that included 458 women with breast cancer in
4 aftercare were included. The different types of exercise consisted of aqua lymph training,
5 swimming, resistance exercise, yoga, aerobic, and gravity-resistive exercise. Four of the
6 studies measured a significant reduction in BCRL status based on arm volume and seven
7 studies reported significant subjective improvements. No study showed adverse effects of
8 exercise on BCRL. Authors concluded that the evidence indicates that exercise can
9 improve subjective and objective parameters in BCRL patients, with dynamic, moderate,
10 and high-frequency exercise appearing to provide the most positive effects. Hasenoehrl et
11 al. (2020) performed a systematic review analyzing resistance exercise (RE) intervention
12 trials in breast cancer survivors (BCS) regarding their effect on breast cancer-related
13 lymphedema (BCRL) status. Authors concluded that RE seems to be a safe exercise
14 intervention for BCS and not to be harmful concerning the risk of lymphedema.
15 Lymphedema assessment methods that allow for a qualitative analysis of arm tissue
16 composition should be favored. At the current time breast cancer related lymphedema is
17 incurable but well manageable by a number of physical therapy modalities, especially
18 complete decongestive therapy (CDT). One of the encouraging treatment methods is
19 resistance exercise.

20
21 Kilbreath et al. (2020) investigated whether an exercise program reduced breast
22 lymphedema symptoms compared to a non-exercise control group. This single-blinded
23 randomized controlled trial was conducted in which women with stable breast lymphedema
24 ($n = 89$) were randomized into an exercise ($n = 41$) or control ($n = 47$) group. The
25 intervention comprised a 12-week combined aerobic and resistance training program,
26 supervised weekly by an accredited exercise physiologist. All participants completed a
27 weekly symptoms diary and were assessed monthly to ensure that there was no
28 exacerbation of their lymphedema. Changes in the breast were captured physically with
29 ultrasound and bioimpedance spectroscopy and changes in symptoms were captured using
30 European Organization for Research and Treatment of Cancer (EORTC) Breast Cancer
31 (BR23) and Lymphedema Symptom Intensity and Distress questionnaires. The exercise
32 group reported a greater reduction in breast-related symptoms than the control group,
33 assessed by the EORTC BR23 breast symptom questions. Measures of extracellular fluid,
34 assessed with bioimpedance spectroscopy ratio, decreased in the exercise group compared
35 to the control group. No significant difference was detected in dermal thickness in the
36 breast, assessed by ultrasound. Session attendance in the exercise sessions was high, with
37 two musculoskeletal adverse events reported, but no exacerbations of lymphedema
38 observed. Authors concluded that combined resistance and aerobic exercise training is safe
39 for women living with breast lymphedema. Preliminary data suggest exercise training can
40 reduce breast lymphedema symptoms to a greater extent than usual care.

1 Saraswathi et al. (2021) systematically reviewed the effect of yoga therapy on managing
2 lymphedema, increasing the range of motion (ROM), and quality of life (QoL) among
3 breast cancer survivors. Studies which assessed the outcome variables such as QoL and
4 management of lymphedema or related physical symptoms as effect of yoga intervention
5 were considered for review. The different styles of yoga employed in the studies were
6 Iyengar yoga ($n = 2$), Satyananda yoga ($n = 2$), Hatha yoga ($n = 2$), and Ashtanga yoga
7 ($n = 1$). The length of intervention and post intervention analysis ranged from 8 weeks to
8 12 months. Authors concluded that yoga could be a safe and feasible exercise intervention
9 for BCRL patients. Evidence generated from these studies was of moderate strength.
10 Further long-term clinical trials with large sample size are essential for the development
11 and standardization of yoga intervention guidelines for BCRL patients.

12
13 Bruce et al. (2021) evaluated whether a structured exercise program improved functional,
14 and health related quality of life outcomes compared with usual care for women at high
15 risk of upper limb disability after breast cancer surgery. Subjects included 392 women
16 undergoing breast cancer surgery, at risk of postoperative upper limb morbidity,
17 randomized (1:1) to usual care with structured exercise ($n=196$) or usual care alone
18 ($n=196$). Usual care (information leaflets) only or usual care plus a physiotherapy led
19 exercise program, incorporating stretching, strengthening, physical activity, and behavioral
20 change techniques to support adherence to exercise, introduced at 7-10 days
21 postoperatively, with two further appointments at one and three months. Main outcome
22 measures included the Disability of Arm, Hand, and Shoulder (DASH) questionnaire at 12
23 months, analyzed by intention to treat. Secondary outcomes included DASH subscales,
24 pain, complications, health related quality of life, and resource use, from a health and
25 personal social services perspective. Upper limb function improved after exercise
26 compared with usual care for exercise. Secondary outcomes favored exercise over usual
27 care, with lower pain intensity at 12 months and fewer arm disability symptoms at 12
28 months. No increase in complications, lymphedema, or adverse events was noted in
29 participants allocated to exercise. Exercise accrued lower costs per patient and was cost
30 effective compared with usual care. Authors concluded that the PROSPER exercise
31 program was clinically effective and cost effective and reduced upper limb disability one
32 year after breast cancer treatment in patients at risk of treatment related postoperative
33 complications.

34
35 Corum et al. (2021) compared the effects of complex decongestive therapy (CDT)
36 accompanied by resistance exercises on extremity circumference, lymphedema volume,
37 grip strength, functional status, and quality of life in the treatment of breast cancer-related
38 lymphedema (BCRL) in patients with and without pain. Fifty patients with unilateral
39 BCRL were divided into groups: with pain (Group 1, $n = 25$) and without pain (Group 2, n
40 $= 25$). Thirty minutes of manual lymphatic drainage and multilayered short-stretch
41 bandaging were applied to all patients five times a week for 4 weeks. In addition, all
42 patients were informed about skin care and given a supervised resistance exercise program

1 throughout the treatment. During the 1-month follow-up period, patients were asked to use
2 low-tension elastic garments and to continue their home exercise program. Differences in
3 upper extremity circumference and volume; grip strength; Quick Disabilities of the Arm,
4 Shoulder, and Hand; and Functional Assessment of Cancer Therapy-Breast scores were
5 evaluated at baseline, after treatment (week 4), and at 1-month follow-up. Moreover, the
6 pain intensity of patients in Group 1 was measured using the visual analog scale (VAS).
7 Patients in both Group 1 and Group 2 showed a statistical improvement in all outcome
8 measures after treatment and at follow-up ($p < 0.05$); however, no significant difference
9 was observed between the groups ($p > 0.05$). In Group 1, a statistically significant decrease
10 was observed in the VAS score both at the end of treatment and at 1-month follow-up ($p <$
11 0.05). Authors concluded that combined CDT and resistance exercises appear to be
12 effective in BCRL patients both with and without pain.

13
14 Hayes et al. (2022) evaluated the effects of exercise on (i) the prevention of cancer-related
15 lymphedema (CRL), and (ii) the treatment of CRL, lymphedema-associated symptoms,
16 and other health outcomes among individuals with CRL in a systematic review and meta-
17 analysis. Twelve studies ($n = 1,955$; 75% moderate-high quality) and 36 studies ($n = 1,741$;
18 58% moderate-high quality) were included in the prevention and treatment aim,
19 respectively. Relative risk of developing CRL for those in the exercise group compared
20 with the non-exercise group was 0.90 overall, and 0.49 for those with 5 or more lymph
21 nodes removed. Improvements post-intervention were observed for pain, upper-body
22 function and strength, lower-body strength, fatigue and quality of life for those in the
23 exercise group. Authors concluded that findings support the application of exercise
24 guidelines for the wider cancer population to those with or at risk of CRL. This includes
25 promotion of aerobic and resistance exercise, and not just resistance exercise alone, as well
26 as unsupervised exercise guided by symptom response.

27
28 Maccarone et al. (2023) evaluated the effects of water-based exercise on pain, limb motor
29 function, quality of life (QoL), and limb volume among patients affected by primary and
30 secondary upper and lower limb lymphedema. The search produced a total of 88 studies.
31 Eight randomized controlled trials and one clinical study of patients with primary or
32 secondary lymphedema of upper or lower limbs who had undergone water-based treatment
33 were included in the present study. Most trials had focused on breast cancer-related
34 lymphedema. The shoulder range of flexion, external rotation, and abduction have been
35 shown to improve after performing a water-based exercise protocol. Some evidence has
36 also demonstrated that the lymphedematous limb strength can improve. Moreover, water-
37 based exercise seemed to improve pain perception and QoL for patients with upper or lower
38 limb lymphedema. In contrast, in the control groups, the QoL showed a tendency to worsen
39 over time. Although some studies had not reported beneficial effects on the
40 lymphedematous limb volume, most of the studies examined had reported a reduction in
41 volume, especially in the short term. No adverse events were reported in the included
42 studies. Authors concluded that these findings from the present review have shown the

1 potential for aquatic exercise in lymphedema management. However, at the same time, the
2 findings underline the multiple limitations resulting from the heterogeneity in the study
3 populations and related physical activity protocols. The role of aquatic exercise in the
4 conservative treatment of lymphedema requires further investigation in the future to define
5 specific protocols of application.

6
7 Lin et al. (2023) sought to determine the effective exercise methods for different
8 complications of breast cancer patients after surgery in a systematic review and meta-
9 analysis. Aerobic exercise reduced the intensity of the pain, improved shoulder flexion and
10 internal rotation range, lessened upper limb dysfunction and improved muscle strength
11 during flexion and abduction. Shoulder elbow movement improved the range of shoulder
12 external rotation and reduced the incidence of arm lymphedema. Anti-resistance exercise
13 also lessened upper limb dysfunction. Wang et al. (2023) This examined the existing best
14 evidence on resistance exercise for BCRL to accurately describe the current status of the
15 field and offer recommendations for clinicians in a systematic, evidence-based review.
16 Twenty-two articles (7 guidelines, 4 consensus documents and 11 systematic reviews) were
17 included. Six clinical topics involving 43 recommendations were identified.
18 Recommendations were categorized by safety of resistance training, effectiveness of
19 resistance training, evaluation prior to resistance exercise, resistance exercise prescription,
20 resistance training outcome index and points for attention. Based on the available research,
21 there is strong evidence evaluating the safety of resistance exercise. The findings support
22 the assertion that breast cancer patients at risk of or with lymphedema should be
23 encouraged to do resistance exercise. Resistance exercise could improve patients' muscle
24 strength and quality of life. Authors also summarized the evidence of resistance exercise
25 prescription which can be used to guide clinical practice. However, there are some
26 inconsistent recommendations in the review, such as the effects of resistance exercise on
27 preventing and relieving lymphedema. The main heterogeneity comes from different
28 exercise prescriptions in terms of exercise type, frequency, intensity, etc. Future studies are
29 needed to provide high-quality evidence for the specificity of exercise prescription, to
30 identify the appropriate exercise volume for patients at different stages of lymphedema or
31 at risk of lymphedema. In terms of whether or not to wear compression garments during
32 exercise, future studies need to focus on patient comfort and compliance with these during
33 exercise: clinicians should not simply take the effects of relieving lymphedema into
34 consideration.

35 36 **Measurement of Lymphedema**

37 Hidding et al. (2016) attempted to provide best evidence of which measurement
38 instruments are most appropriate in measuring lymphedema in its different stages. Authors
39 concluded that measurement instruments with evidence for good reliability and validity are
40 Bioelectrical Impedance Spectroscopy (BIS), water volumetry, tape measurement and
41 perometry, where BIS can detect alterations in extracellular fluid in stage 1 lymphedema
42 and the other measurement instruments alterations in volume starting from stage 2. In

1 research water volumetry is indicated as reference test for measuring lymphedema in upper
2 extremities. Limitations included the following: no uniform definition of lymphedema was
3 available and a gold standard as reference test was lacking. Items concerning risk of bias
4 were study design, patient selection, description of lymphedema, blinding of test outcomes
5 and number of included patients.

6
7 Şahinoğlu et al. (2024) evaluated the agreement between the American Physical Therapy
8 Association (APTA) criteria, the criteria of Ramos et al., and the International Society of
9 Lymphology (ISL) criteria in patients with upper and lower extremity lymphedema.
10 Several classification systems are used to grade the severity of lymphedema. Their
11 agreement with each other has not been reported. A total of 156 patients (63 and 93 patients
12 with upper and lower extremity lymphedema, respectively) were included. The
13 circumference measurements and limb volume were measured. The severity of
14 lymphedema of the patients was classified as mild, moderate, and severe lymphedema
15 using the APTA criteria, the criteria of Ramos et al., and the ISL criteria. An acceptable
16 and poor agreement were found between the criteria in upper and lower extremity
17 lymphedema, respectively. In pairwise comparisons, an acceptable agreement was found
18 among each comparison in upper extremity lymphedema, and a poor agreement was found
19 among each comparison in lower extremity lymphedema except between the APTA criteria
20 and the criteria of Ramos et al. Authors concluded that patients with upper extremity
21 lymphedema classified according to these criteria can be assumed to be samples of the
22 same population; however, patients with lower extremity lymphedema graded according
23 to the ISL criteria may be included in a different classification when they grade with the
24 APTA criteria and the criteria of Ramos et al.

25 26 **PRACTITIONER SCOPE AND TRAINING**

27 Practitioners should practice only in the areas in which they are competent based on their
28 education, training, and experience. Levels of education, experience, and proficiency may
29 vary among individual practitioners. It is ethically and legally incumbent on a practitioner
30 to determine where they have the knowledge and skills necessary to perform such services
31 and whether the services are within their scope of practice.

32
33 It is best practice for the practitioner to appropriately render services to a member only if
34 they are trained, equally skilled, and adequately competent to deliver a service compared
35 to others trained to perform the same procedure. If the service would be most competently
36 delivered by another health care practitioner who has more skill and training, it would be
37 best practice to refer the member to the more expert practitioner.

38
39 Best practice can be defined as a clinical, scientific, or professional technique, method, or
40 process that is typically evidence-based and consensus driven and is recognized by a
41 majority of professionals in a particular field as more effective at delivering a particular

1 outcome than any other practice (Joint Commission International Accreditation Standards
2 for Hospitals, 2020).

3
4 Depending on the practitioner’s scope of practice, training, and experience, a member’s
5 condition and/or symptoms during examination or the course of treatment may indicate the
6 need for referral to another practitioner or even emergency care. In such cases it is prudent
7 for the practitioner to refer the member for appropriate co-management (e.g., to their
8 primary care physician) or if immediate emergency care is warranted, to contact 911 as
9 appropriate. See the *Managing Medical Emergencies (CPG 159 – S)* clinical practice
10 guideline for information.

11 REFERENCES

12 Ahmed Omar, M. T., Abd-El-Gayed Ebid, A., & El Morsy, A. M. (2011). Treatment of
13 post-mastectomy lymphedema with laser therapy: double blind placebo control
14 randomized study. *The Journal of surgical research*, 165(1), 82–90.
15 <https://doi.org/10.1016/j.jss.2010.03.050>
16

17
18 Andersen, L., Højris, I., Erlandsen, M., & Andersen, J. (2000). Treatment of breast-cancer-
19 related lymphedema with or without manual lymphatic drainage--a randomized
20 study. *Acta oncologica (Stockholm, Sweden)*, 39(3), 399–405.
21 <https://doi.org/10.1080/028418600750013186>
22

23 Badger, C., Preston, N., Seers, K., & Mortimer, P. (2004). Physical therapies for reducing
24 and controlling lymphoedema of the limbs. *The Cochrane database of systematic*
25 *reviews*, (4), CD003141. <https://doi.org/10.1002/14651858.CD003141.pub2>
26

27 Bakar, Y., & Tuğral, A. (2017). Lower Extremity Lymphedema Management after
28 Gynecologic Cancer Surgery: A Review of Current Management Strategies. *Annals of*
29 *vascular surgery*, 44, 442–450. <https://doi.org/10.1016/j.avsg.2017.03.197>
30

31 Baumann FT, Reike A, Reimer V, Schumann M, Hallek M, Taaffe DR, Newton RU,
32 Galvao DA. Effects of physical exercise on breast cancer-related secondary
33 lymphedema: a systematic review. *Breast Cancer Res Treat.* 2018 Jul;170(1):1-13
34

35 Baxter GD, Liu L, Petrich S, Gisselman AS, Chapple C, Anders JJ, Tumilty S. Low level
36 laser therapy (Photobiomodulation therapy) for breast cancer-related lymphedema: a
37 systematic review. *BMC Cancer.* 2017 Dec 7;17(1):833
38

39 Białoszewski, D., Woźniak, W., & Zarek, S. (2009). Clinical efficacy of kinesiology taping
40 in reducing edema of the lower limbs in patients treated with the ilizarov method--
41 preliminary report. *Ortopedia, traumatologia, rehabilitacja*, 11(1), 46–54

- 1 Bicego, D., Brown, K., Ruddick, M., Storey, D., Wong, C., & Harris, S. R. (2006). Exercise
2 for women with or at risk for breast cancer-related lymphedema. *Physical*
3 *therapy*, 86(10), 1398–1405. <https://doi.org/10.2522/ptj.20050328>
4
- 5 Borman P, Yaman A, Yasrebi S, Pinar İnanlı A, Arıkan Dönmez A. Combined Complete
6 Decongestive Therapy Reduces Volume and Improves Quality of Life and Functional
7 Status in Patients With Breast Cancer-Related Lymphedema. *Clin Breast Cancer*.
8 2022;22(3):e270-e277. doi:10.1016/j.clbc.2021.08.005
9
- 10 Bosman J. (2014). Lymph taping for lymphoedema: an overview of the treatment and its
11 uses. *British journal of community nursing, Suppl*, S12–S18.
12 <https://doi.org/10.12968/bjcn.2014.19.sup4.s12>
13
- 14 Buchan, J., Janda, M., Box, R., Schmitz, K., & Hayes, S. (2016). A Randomized Trial on
15 the Effect of Exercise Mode on Breast Cancer-Related Lymphedema. *Medicine and*
16 *science in sports and exercise*, 48(10), 1866–1874.
17 <https://doi.org/10.1249/MSS.0000000000000988>
18
- 19 Canadian Agency for Drugs and Technologies in Health (CADTH). Health Technology
20 Inquiry Service. (2010). Manual lymph drainage or intermittent pneumatic
21 compression for adult patients with secondary lymphedema: clinical effectiveness.
22 Health Technology Assessment. Accessed July 11, 2024 from
23 https://www.cadth.ca/sites/default/files/pdf/k0173_lymphedema_htis-L1-5.pdf
24
- 25 Canadian Agency for Drugs and Technologies in Health (CADTH). Health Technology
26 Inquiry Service. (2011). Compression Garments for the Treatment of Primary and
27 Secondary Lymphedema: Clinical Effectiveness and Guidelines. Accessed July 11,
28 2024 from [https://www.cadth.ca/sites/default/files/pdf/htis/oct-2011/RB0437-](https://www.cadth.ca/sites/default/files/pdf/htis/oct-2011/RB0437-000%20Lymphedema.pdf)
29 [000%20Lymphedema.pdf](https://www.cadth.ca/sites/default/files/pdf/htis/oct-2011/RB0437-000%20Lymphedema.pdf)
30
- 31 Carati, C. J., Anderson, S. N., Gannon, B. J., & Piller, N. B. (2003). Treatment of
32 postmastectomy lymphedema with low-level laser therapy: a double blind, placebo-
33 controlled trial. *Cancer*, 98(6), 1114–1122. <https://doi.org/10.1002/cncr.11641>
34
- 35 Casley-Smith, J. R., Boris, M., Weindorf, S., & Lasinski, B. (1998). Treatment for
36 lymphedema of the arm--the Casley-Smith method: a noninvasive method produces
37 continued reduction. *Cancer*, 83(12 Suppl American), 2843–2860.
38 [https://doi.org/10.1002/\(sici\)1097-0142\(19981215\)83:12b+<2843::aid-](https://doi.org/10.1002/(sici)1097-0142(19981215)83:12b+<2843::aid-cncr38>3.3.co;2-1)
39 [cncr38>3.3.co;2-1](https://doi.org/10.1002/(sici)1097-0142(19981215)83:12b+<2843::aid-cncr38>3.3.co;2-1)

- 1 Chaput G, Ibrahim M. Cancer-related lymphedema. *Can Fam Physician*. 2023
2 Oct;69(10):691-695.
- 3
- 4 Cheifetz, O., Haley, L., & Breast Cancer Action (2010). Management of secondary
5 lymphedema related to breast cancer. *Canadian family physician Medecin de famille*
6 *canadien*, 56(12), 1277–1284
- 7
- 8 Cheng JT, Leite VF, Tennison JM, Gutierrez C, Kline-Quiroz C, Capozzi LC, Yu S, Krause
9 KJ, Langelier D, Parke SC. Rehabilitation Interventions for Head and Neck Cancer-
10 Associated Lymphedema: A Systematic Review. *JAMA Otolaryngol Head Neck Surg*.
11 2023 Aug 1;149(8):743-753.
- 12
- 13 Chiu ST, Lai UH, Huang YC, Leong CP, Chen PC. Effect of various photobiomodulation
14 regimens on breast cancer-related lymphedema: A systematic review and meta-
15 analysis. *Lasers Med Sci*. 2023 Dec 22;39(1):11.
- 16
- 17 Cormier, J. N., Askew, R. L., Mungovan, K. S., Xing, Y., Ross, M. I., & Armer, J. M.
18 (2010). Lymphedema beyond breast cancer: a systematic review and meta-analysis of
19 cancer-related secondary lymphedema. *Cancer*, 116(22), 5138–5149.
20 <https://doi.org/10.1002/cncr.25458>
- 21
- 22 Corum M, Basoglu C, Korkmaz MD, Yildirim MA, Ones K. Effectiveness of Combined
23 Complex Decongestive Therapy and Resistance Exercises in the Treatment of
24 Lymphedema Associated with Breast Cancer and the Effect of Pain on Treatment
25 Response. *Lymphat Res Biol*. 2021;19(4):383-390. doi:10.1089/lrb.2020.0099
- 26
- 27 Dayes, I. S., Whelan, T. J., Julian, J. A., Parpia, S., Pritchard, K. I., D'Souza, D. P.,
28 Kligman, L., Reise, D., LeBlanc, L., McNeely, M. L., Manchul, L., Wiernikowski, J.,
29 & Levine, M. N. (2013). Randomized trial of decongestive lymphatic therapy for the
30 treatment of lymphedema in women with breast cancer. *Journal of clinical oncology :*
31 *official journal of the American Society of Clinical Oncology*, 31(30), 3758–3763.
32 <https://doi.org/10.1200/JCO.2012.45.7192>
- 33
- 34 Devoogdt, N., Van Kampen, M., Geraerts, I., Coremans, T., & Christiaens, M. R. (2010).
35 Different physical treatment modalities for lymphoedema developing after axillary
36 lymph node dissection for breast cancer: a review. *European journal of obstetrics,*
37 *gynecology, and reproductive biology*, 149(1), 3–9
- 38
- 39 De Vrieze T, Gebruers N, Nevelsteen I, et al. Manual lymphatic drainage with or without
40 fluoroscopy guidance did not substantially improve the effect of decongestive
41 lymphatic therapy in people with breast cancer-related lymphoedema (EforT-BCRL

- 1 trial): a multicentre randomised trial. *J Physiother.* 2022;68(2):110-122.
2 doi:10.1016/j.jphys.2022.03.010
3
- 4 Didem, K., Ufuk, Y. S., Serdar, S., & Zümre, A. (2005). The comparison of two different
5 physiotherapy methods in treatment of lymphedema after breast surgery. *Breast cancer*
6 *research and treatment*, 93(1), 49–54
7
- 8 Dirican, A., Andacoglu, O., Johnson, R., McGuire, K., Mager, L., & Soran, A. (2011). The
9 short-term effects of low-level laser therapy in the management of breast-cancer-
10 related lymphedema. *Supportive care in cancer : official journal of the Multinational*
11 *Association of Supportive Care in Cancer*, 19(5), 685–690.
12 <https://doi.org/10.1007/s00520-010-0888-8>
13
- 14 Do, J. H., Choi, K. H., Ahn, J. S., & Jeon, J. Y. (2017). Effects of a complex rehabilitation
15 program on edema status, physical function, and quality of life in lower-limb
16 lymphedema after gynecological cancer surgery. *Gynecologic oncology*, 147(2), 450–
17 455. <https://doi.org/10.1016/j.ygyno.2017.09.003>
18
- 19 Donahue PMC, MacKenzie A, Filipovic A, Koelmeyer L. Advances in the prevention and
20 treatment of breast cancer-related lymphedema. *Breast Cancer Res Treat.* 2023
21 Jul;200(1):1-14.
22
- 23 Executive Committee (2016). The Diagnosis and Treatment of Peripheral Lymphedema:
24 2016 Consensus Document of the International Society of
25 Lymphology. *Lymphology*, 49(4), 170–184
26
- 27 Executive Committee of the International Society of Lymphology. The diagnosis and
28 treatment of peripheral lymphedema: 2020 Consensus Document of the International
29 Society of Lymphology. *Lymphology* 2020, 53, 3–19
30
- 31 Ezzo, J., Manheimer, E., McNeely, M. L., Howell, D. M., Weiss, R., Johansson, K. I., Bao,
32 T., Bily, L., Tuppo, C. M., Williams, A. F., & Karadibak, D. (2015). Manual lymphatic
33 drainage for lymphedema following breast cancer treatment. *The Cochrane database of*
34 *systematic reviews*, (5), CD003475.
35 <https://doi.org/10.1002/14651858.CD003475.pub2>
36
- 37 Finnane, A., Janda, M., & Hayes, S. C. (2015). Review of the evidence of lymphedema
38 treatment effect. *American journal of physical medicine & rehabilitation*, 94(6), 483–
39 498. <https://doi.org/10.1097/PHM.0000000000000246>

- 1 Földi E. (1998). The treatment of lymphedema. *Cancer*, 83(12 Suppl American), 2833–
2 2834. [https://doi.org/10.1002/\(sici\)1097-0142\(19981215\)83:12b+<2833::aid-](https://doi.org/10.1002/(sici)1097-0142(19981215)83:12b+<2833::aid-cncr35>3.0.co;2-3)
3 [cncr35>3.0.co;2-3](https://doi.org/10.1002/(sici)1097-0142(19981215)83:12b+<2833::aid-cncr35>3.0.co;2-3)
4
- 5 Forner-Cordero I, Muñoz-Langa J, DeMiguel-Jimeno JM, Rel-Monzó P. Physical
6 therapies in the decongestive treatment of lymphedema: A randomized, non-inferiority
7 controlled study. *Clin Rehabil.* 2021;35(12):1743-1756.
8 doi:10.1177/02692155211032651
9
- 10 Fu, Mei R et al. “Putting evidence into practice: cancer-related lymphedema.” *Clinical*
11 *journal of oncology nursing* vol. 18 Suppl (2014): 68-79. doi:10.1188/14.CJON.S3.68-
12 79
13
- 14 Gatt, M., Willis, S., & Leuschner, S. (2017). A meta-analysis of the effectiveness and safety
15 of kinesiology taping in the management of cancer-related lymphoedema. *European*
16 *journal of cancer care*, 26(5), 10.1111/ecc.12510
17
- 18 Golshan, M., & Smith, B. (2006). Prevention and management of arm lymphedema in the
19 patient with breast cancer. *The journal of supportive oncology*, 4(8), 381–386
20
- 21 Haghghat, S., Lotfi-Tokaldany, M., Yunesian, M., Akbari, M. E., Nazemi, F., & Weiss, J.
22 (2010). Comparing two treatment methods for post mastectomy lymphedema: complex
23 decongestive therapy alone and in combination with intermittent pneumatic
24 compression. *Lymphology*, 43(1), 25–33
25
- 26 Hamner, J. B., & Fleming, M. D. (2007). Lymphedema therapy reduces the volume of
27 edema and pain in patients with breast cancer. *Annals of surgical oncology*, 14(6),
28 1904–1908. <https://doi.org/10.1245/s10434-006-9332-1>
29
- 30 Harris, S. R., Hugi, M. R., Olivotto, I. A., Levine, M., & Steering Committee for Clinical
31 Practice Guidelines for the Care and Treatment of Breast Cancer (2001). *Clinical*
32 *practice guidelines for the care and treatment of breast cancer: 11.*
33 *Lymphedema. CMAJ : Canadian Medical Association journal = journal de*
34 *l'Association medicale canadienne*, 164(2), 191–199
35
- 36 Hasenoehrl T, Keilani M, Palma S, Crevenna R. Resistance exercise and breast cancer
37 related lymphedema - a systematic review update. *Disabil Rehabil.* 2020 Jan;42(1):26-
38 35
39
- 40 Hayes SC, Singh B, Reul-Hirche H, et al. The Effect of Exercise for the Prevention and
41 Treatment of Cancer-related Lymphedema: A Systematic Review with Meta-analysis

1 [published online ahead of print, 2022 Mar 22]. *Med Sci Sports Exerc.*
 2 2022;10.1249/MSS.0000000000002918

3
 4 Hidding, J. T., Viehoff, P. B., Beurskens, C. H., van Laarhoven, H. W., Nijhuis-van der
 5 Sanden, M. W., & van der Wees, P. J. (2016). Measurement Properties of Instruments
 6 for Measuring of Lymphedema: Systematic Review. *Physical therapy*, 96(12), 1965–
 7 1981. <https://doi.org/10.2522/ptj.20150412>

8
 9 Hwang, J. M., Hwang, J. H., Kim, T. W., Lee, S. Y., Chang, H. J., & Chu, I. H. (2013).
 10 Long-term effects of complex decongestive therapy in breast cancer patients with arm
 11 lymphedema after axillary dissection. *Annals of rehabilitation medicine*, 37(5), 690–
 12 697

13
 14 International Society of Lymphology (2003). The diagnosis and treatment of peripheral
 15 lymphedema. Consensus document of the International Society of
 16 Lymphology. *Lymphology*, 36(2), 84–91

17
 18 International Society of Lymphology (2009). The diagnosis and treatment of peripheral
 19 lymphedema. 2009 Consensus Document of the International Society of
 20 Lymphology. *Lymphology*, 42(2), 51–60

21
 22 International Society of Lymphology. The diagnosis and treatment of peripheral
 23 lymphedema. Consensus document of the International Society of Lymphology. 2020.
 24 Retrieved on June 20, 2024 from [https://isl.arizona.edu/sites/default/files/2021-
 25 09/Consensus%20Document-SM.pdf](https://isl.arizona.edu/sites/default/files/2021-09/Consensus%20Document-SM.pdf)

26
 27 Johansson, K., Karlsson, K., & Nikolaidis, P. (2015). Evidence-based or traditional
 28 treatment of cancer-related lymphedema. *Lymphology*, 48(1), 24–27

29
 30 Kalemikerakis I, Evaggelakou A, Kavga A, Vastardi M, Konstantinidis T, Govina O.
 31 Diagnosis, treatment and quality of life in patients with cancer-related lymphedema. *J*
 32 *BUON*. 2021;26(5):1735-1741

33
 34 Kalron, A., & Bar-Sela, S. (2013). A systematic review of the effectiveness of Kinesio
 35 Taping--fact or fashion?. *European journal of physical and rehabilitation*
 36 *medicine*, 49(5), 699–709

37
 38 Karadibak, D., Yavuzsen, T., & Saydam, S. (2008). Prospective trial of intensive
 39 decongestive physiotherapy for upper extremity lymphedema. *Journal of surgical*
 40 *oncology*, 97(7), 572–577. <https://doi.org/10.1002/jso.21035>

- 1 Kärki, A., Anttila, H., Tasmuth, T., & Rautakorpi, U. M. (2009). Lymphoedema therapy
2 in breast cancer patients: a systematic review on effectiveness and a survey of current
3 practices and costs in Finland. *Acta oncologica* (Stockholm, Sweden), 48(6), 850–859.
4 <https://doi.org/10.1080/02841860902755251>
- 5
- 6 Kasseroller R. G. (1998). The Vodder School: the Vodder method. *Cancer*, 83(12 Suppl
7 American), 2840–2842.
- 8
- 9 Kilbreath SL, Ward LC, Davis GM, Degnim AC, Hackett DA, Skinner TL, Black D.
10 Reduction of breast lymphoedema secondary to breast cancer: a randomised controlled
11 exercise trial. *Breast Cancer Res Treat.* 2020 Nov;184(2):459-467. doi:
12 10.1007/s10549-020-05863-4
- 13
- 14 Kim, D. S., Sim, Y. J., Jeong, H. J., & Kim, G. C. (2010). Effect of active resistive exercise
15 on breast cancer-related lymphedema: a randomized controlled trial. *Archives of*
16 *physical medicine and rehabilitation*, 91(12), 1844–1848.
17 <https://doi.org/10.1016/j.apmr.2010.09.008>
- 18
- 19 Kim, S. J., & Park, Y. D. (2008). Effects of complex decongestive physiotherapy on the
20 oedema and the quality of life of lower unilateral lymphoedema following treatment
21 for gynecological cancer. *European journal of cancer care*, 17(5), 463–468.
22 <https://doi.org/10.1111/j.1365-2354.2007.00877.x>
- 23
- 24 Kligman, L., Wong, R. K., Johnston, M., & Laetsch, N. S. (2004). The treatment of
25 lymphedema related to breast cancer: a systematic review and evidence
26 summary. *Supportive care in cancer : official journal of the Multinational Association*
27 *of Supportive Care in Cancer*, 12(6), 421–431. [https://doi.org/10.1007/s00520-004-](https://doi.org/10.1007/s00520-004-0627-0)
28 [0627-0](https://doi.org/10.1007/s00520-004-0627-0)
- 29
- 30 Koul, R., Dufan, T., Russell, C., Guenther, W., Nugent, Z., Sun, X., & Cooke, A. L. (2007).
31 Efficacy of complete decongestive therapy and manual lymphatic drainage on
32 treatment-related lymphedema in breast cancer. *International journal of radiation*
33 *oncology, biology, physics*, 67(3), 841–846.
34 <https://doi.org/10.1016/j.ijrobp.2006.09.024>
- 35
- 36 Kozanoglu, E., Basaran, S., Paydas, S., & Sarpel, T. (2009). Efficacy of pneumatic
37 compression and low-level laser therapy in the treatment of postmastectomy
38 lymphoedema: a randomized controlled trial. *Clinical rehabilitation*, 23(2), 117–124.
39 <https://doi.org/10.1177/0269215508096173>
- 40
- 41 Kozanoglu E, Gokcen N, Basaran S, Paydas S. Long-Term Effectiveness of Combined
42 Intermittent Pneumatic Compression Plus Low-Level Laser Therapy in Patients with

- 1 Postmastectomy Lymphedema: A Randomized Controlled Trial. *Lymphat Res Biol.*
 2 2022;20(2):175-184. doi:10.1089/lrb.2020.0132
 3
- 4 Kwan, M. L., Cohn, J. C., Armer, J. M., Stewart, B. R., & Cormier, J. N. (2011). Exercise
 5 in patients with lymphedema: a systematic review of the contemporary
 6 literature. *Journal of cancer survivorship : research and practice*, 5(4), 320–336.
 7 <https://doi.org/10.1007/s11764-011-0203-9>
 8
- 9 Lasinski B. B. (2013). Complete decongestive therapy for treatment of
 10 lymphedema. *Seminars in oncology nursing*, 29(1), 20–27.
 11 <https://doi.org/10.1016/j.soncn.2012.11.004>
 12
- 13 Lasinski B.B. Boris M. (2002). Comprehensive lymphedema management: results of a 5
 14 year follow-up. *Lymphology*, 35 (suppl):301-4
 15
- 16 Lasinski, B. B., McKillip Thrift, K., Squire, D., Austin, M. K., Smith, K. M., Wanchai, A.,
 17 Green, J. M., Stewart, B. R., Cormier, J. N., & Armer, J. M. (2012). A systematic
 18 review of the evidence for complete decongestive therapy in the treatment of
 19 lymphedema from 2004 to 2011. *PM & R : the journal of injury, function, and*
 20 *rehabilitation*, 4(8), 580–601. <https://doi.org/10.1016/j.pmrj.2012.05.003>
 21
- 22 Lawenda, B. D., Mondry, T. E., & Johnstone, P. A. (2009). Lymphedema: a primer on the
 23 identification and management of a chronic condition in oncologic treatment. *CA: a*
 24 *cancer journal for clinicians*, 59(1), 8–24. <https://doi.org/10.3322/caac.20001>
 25
- 26 Leal, N. F., Carrara, H. H., Vieira, K. F., & Ferreira, C. H. (2009). Physiotherapy treatments
 27 for breast cancer-related lymphedema: a literature review. *Revista latino-americana de*
 28 *enfermagem*, 17(5), 730–736. <https://doi.org/10.1590/s0104-11692009000500021>
 29
- 30 Leung, E. Y., Tirlapur, S. A., & Meads, C. (2015). The management of secondary lower
 31 limb lymphoedema in cancer patients: a systematic review. *Palliative medicine*, 29(2),
 32 112–119. <https://doi.org/10.1177/0269216314545803>
 33
- 34 Lin Y, Yang Y, Zhang X, Li W, Li H, Mu D. Manual Lymphatic Drainage for Breast
 35 Cancer-related Lymphedema: A Systematic Review and Meta-analysis of Randomized
 36 Controlled Trials. *Clin Breast Cancer.* 2022;22(5):e664-e673.
 37 doi:10.1016/j.clbc.2022.01.013
 38
- 39 Lin Y, Chen Y, Liu R, Cao B. Effect of exercise on rehabilitation of breast cancer surgery
 40 patients: A systematic review and meta-analysis of randomized controlled trials. *Nurs*
 41 *Open.* 2023 Apr;10(4):2030-2043.

- 1 Maccarone MC, Venturini E, Menegatti E, Giancesini S, Masiero S. Water-based exercise
2 for upper and lower limb lymphedema treatment. *J Vasc Surg Venous Lymphat Disord.*
3 2023;11(1):201-209. doi:10.1016/j.jvsv.2022.08.002
4
- 5 Macdonald, J. M., Sims, N., & Mayrovitz, H. N. (2003). Lymphedema, lipedema, and the
6 open wound: the role of compression therapy. *The Surgical clinics of North*
7 *America*, 83(3), 639–658. [https://doi.org/10.1016/S0039-6109\(02\)00201-3](https://doi.org/10.1016/S0039-6109(02)00201-3)
8
- 9 Marotta N, Lippi L, Ammendolia V, Calafiore D, Inzitari MT, Pinto M, Invernizzi M, de
10 Sire A. Efficacy of kinesio taping on upper limb volume reduction in patients with
11 breast cancer-related lymphedema: a systematic review of randomized controlled trials.
12 *Eur J Phys Rehabil Med.* 2023 Apr;59(2):237-247.
13
- 14 McNeely, M. L., Magee, D. J., Lees, A. W., Bagnall, K. M., Haykowsky, M., & Hanson,
15 J. (2004). The addition of manual lymph drainage to compression therapy for breast
16 cancer related lymphedema: a randomized controlled trial. *Breast cancer research and*
17 *treatment*, 86(2), 95–106. <https://doi.org/10.1023/B:BREA.0000032978.67677.9f>
18
- 19 McNeely ML, Dolgoy ND, Rafn BS, et al. Nighttime compression supports improved self-
20 management of breast cancer-related lymphedema: A multicenter randomized
21 controlled trial. *Cancer.* 2022;128(3):587-596. doi:10.1002/cncr.33943
22
- 23 Megens, A., & Harris, S. R. (1998). Physical therapist management of lymphedema
24 following treatment for breast cancer: a critical review of its effectiveness. *Physical*
25 *therapy*, 78(12), 1302–1311. <https://doi.org/10.1093/ptj/78.12.1302>
26
- 27 Michopoulos E, Papathanasiou G, Vasilopoulos G, Polikandrioti M, Dimakakos E.
28 Effectiveness and Safety of Complete Decongestive Therapy of Phase I: A
29 Lymphedema Treatment Study in the Greek Population. *Cureus.* 2020 Jul
30 19;12(7):e9264. doi: 10.7759/cureus.9264
31
- 32 Mondry, T. E., Riffenburgh, R. H., & Johnstone, P. A. (2004). Prospective trial of complete
33 decongestive therapy for upper extremity lymphedema after breast cancer
34 therapy. *Cancer journal (Sudbury, Mass.)*, 10(1), 42–19.
35 <https://doi.org/10.1097/00130404-200401000-00009>
36
- 37 Morris, D et al. “The clinical effects of Kinesio® Tex taping: A systematic
38 review.” *Physiotherapy theory and practice* vol. 29,4 (2013): 259-70.
39 doi:10.3109/09593985.2012.731675
40
- 41 Moseley, A. L., Carati, C. J., & Piller, N. B. (2007). A systematic review of common
42 conservative therapies for arm lymphoedema secondary to breast cancer

1 treatment. *Annals of oncology : official journal of the European Society for Medical*
 2 *Oncology*, 18(4), 639–646. <https://doi.org/10.1093/annonc/mdl182>

3
 4 National Cancer Institute (NCI). Lymphedema [Physician Data Query (PDQ®)]. Last
 5 Modified: 2023. Retrieved on June 20, 2024 from
 6 [http://www.cancer.gov/cancertopics/pdq/supportivecare/lymphedema/healthprofessio](http://www.cancer.gov/cancertopics/pdq/supportivecare/lymphedema/healthprofessional/AllPages)
 7 [nal/AllPages](http://www.cancer.gov/cancertopics/pdq/supportivecare/lymphedema/healthprofessional/AllPages)

8
 9 National Lymphedema Network (NLN). Position statement of the national lymphedema
 10 network. *The Diagnosis And Treatment Of Lymphedema*. February 2011. Currently
 11 under review and revision. Retrieved on June 13, 2022 from
 12 [https://13gkfrf50081srbm42cuf1bf-wpengine.netdna-ssl.com/wp-](https://13gkfrf50081srbm42cuf1bf-wpengine.netdna-ssl.com/wp-content/uploads/2016/02/2011_NLN_Position-Statement-of-NLN.pdf)
 13 [content/uploads/2016/02/2011_NLN_Position-Statement-of-NLN.pdf](https://13gkfrf50081srbm42cuf1bf-wpengine.netdna-ssl.com/wp-content/uploads/2016/02/2011_NLN_Position-Statement-of-NLN.pdf)

14
 15 National Lymphedema Network (NLN). Position statement of the national lymphedema
 16 network. Exercise. December 2011. Accessed March 26, 2024. Available at URL
 17 address:
 18 [https://static1.squarespace.com/static/5b741fa71aef1d1e6500b325/t/621c4b9fd98583](https://static1.squarespace.com/static/5b741fa71aef1d1e6500b325/t/621c4b9fd985833faafd4117/1646021535820/Exercise.pdf)
 19 [3faafd4117/1646021535820/Exercise.pdf](https://static1.squarespace.com/static/5b741fa71aef1d1e6500b325/t/621c4b9fd985833faafd4117/1646021535820/Exercise.pdf)

20
 21 Nelson NL. Breast Cancer-Related Lymphedema and Resistance Exercise: A Systematic
 22 Review. *J Strength Cond Res*. 2016 Sep;30(9):2656-65

23
 24 Oremus, M., Dayes, I., Walker, K., & Raina, P. (2012). Systematic review: conservative
 25 treatments for secondary lymphedema. *BMC cancer*, 12, 6.
 26 <https://doi.org/10.1186/1471-2407-12-6>

27
 28 Oremus, M., Walker, K., Dayes, I., & Raina, P. (2010). Diagnosis and Treatment of
 29 Secondary Lymphedema. Agency for Healthcare Research and Quality (US)

30
 31 Pekyavaş, N. Ö., Tunay, V. B., Akbayrak, T., Kaya, S., & Karataş, M. (2014). Complex
 32 decongestive therapy and taping for patients with postmastectomy lymphedema: a
 33 randomized controlled study. *European journal of oncology nursing : the official*
 34 *journal of European Oncology Nursing Society*, 18(6), 585–590.
 35 <https://doi.org/10.1016/j.ejon.2014.06.010>

36
 37 Petrek, J. A., Pressman, P. I., & Smith, R. A. (2000). Lymphedema: current issues in
 38 research and management. *CA: a cancer journal for clinicians*, 50(5), 292–311.
 39 <https://doi.org/10.3322/canjclin.50.5.292>

40
 41 Poage, E., Singer, M., Armer, J., Poundall, M., & Shellabarger, M. J. (2008). Demystifying
 42 lymphedema: development of the lymphedema putting evidence into practice

- 1 card. *Clinical journal of oncology nursing*, 12(6), 951–964.
2 <https://doi.org/10.1188/08.CJON.951-964>
3
- 4 Qiao J, Yang LN, Kong YH, Huang X, Li Y, Bai DQ. Effect of Manual Lymphatic
5 Drainage on Breast Cancer-Related Postmastectomy Lymphedema: A Meta-analysis
6 of Randomized Controlled Trials. *Cancer Nurs.* 2023;46(2):159-166.
7 doi:10.1097/NCC.0000000000001061
8
- 9 Rangon FB, da Silva J, Dibai-Filho AV, Guirro RRJ, Guirro ECO. Effects of Complex
10 Physical Therapy and Multimodal Approaches on Lymphedema Secondary to Breast
11 Cancer: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
12 *Arch Phys Med Rehabil.* 2022;103(2):353-363
13
- 14 Ridner S. H. (2002). Breast cancer lymphedema: pathophysiology and risk reduction
15 guidelines. *Oncology nursing forum*, 29(9), 1285–1293.
16 <https://doi.org/10.1188/02.ONF.1285-1293>
17
- 18 Ryans K, Perdomo M, Davies CC, Levenhagen K, Gilchrist L. Rehabilitation interventions
19 for the management of breast cancer-related lymphedema: developing a patient-
20 centered, evidence-based plan of care throughout survivorship. *J Cancer Surviv.*
21 2023;17(1):237-245. doi:10.1007/s11764-021-00991-2
22
- 23 Şahinoğlu E, Ergin G, Karadibak D. The agreement between three classification systems
24 used to grade the severity of lymphedema in patients with upper and lower extremity
25 lymphedema: A retrospective study. *Physiother Theory Pract.* 2024 Apr;40(4):874-
26 879.
27
- 28 Saraswathi, V., Latha, S., Niraimathi, K., & Vidhubala, E. (2021). Managing
29 Lymphedema, Increasing Range of Motion, and Quality of Life through Yoga Therapy
30 among Breast Cancer Survivors: A Systematic Review. *International journal of*
31 *yoga*, 14(1), 3–17. https://doi.org/10.4103/ijoy.IJOY_73_19
32
- 33 Senger JB, Kadle RL, Skoracki RJ. Current Concepts in the Management of Primary
34 Lymphedema. *Medicina (Kaunas).* 2023 May 6;59(5):894.
35
- 36 Sezgin Ozcan, D., Dalyan, M., Unsal Delialioglu, S., Duzlu, U., Polat, C. S., & Koseoglu,
37 B. F. (2018). Complex Decongestive Therapy Enhances Upper Limb Functions in
38 Patients with Breast Cancer-Related Lymphedema. *Lymphatic research and*
39 *biology*, 16(5), 446–452. <https://doi.org/10.1089/lrb.2017.0061>
40
- 41 Shao, Y., Qi, K., Zhou, Q. H., & Zhong, D. S. (2014). Intermittent pneumatic compression
42 pump for breast cancer-related lymphedema: a systematic review and meta-analysis of

- 1 randomized controlled trials. *Oncology research and treatment*, 37(4), 170–174.
 2 <https://doi.org/10.1159/000360786>
 3
- 4 Smoot, B., Chiavola-Larson, L., Lee, J., Manibusan, H., & Allen, D. D. (2015). Effect of
 5 low-level laser therapy on pain and swelling in women with breast cancer-related
 6 lymphedema: a systematic review and meta-analysis. *Journal of cancer survivorship :
 7 research and practice*, 9(2), 287–304. <https://doi.org/10.1007/s11764-014-0411-1>
 8
- 9 Stout Gergich, N. L., Pfalzer, L. A., McGarvey, C., Springer, B., Gerber, L. H., & Soballe,
 10 P. (2008). Preoperative assessment enables the early diagnosis and successful treatment
 11 of lymphedema. *Cancer*, 112(12), 2809–2819. <https://doi.org/10.1002/cncr.23494>
 12
- 13 Szolnoky, G., Lakatos, B., Keskeny, T., Varga, E., Varga, M., Dobozy, A., & Kemény, L.
 14 (2009). Intermittent pneumatic compression acts synergistically with manual lymphatic
 15 drainage in complex decongestive physiotherapy for breast cancer treatment-related
 16 lymphedema. *Lymphology*, 42(4), 188–194
 17
- 18 Szuba, A., Cooke, J. P., Yousuf, S., & Rockson, S. G. (2000). Decongestive lymphatic
 19 therapy for patients with cancer-related or primary lymphedema. *The American journal
 20 of medicine*, 109(4), 296–300. [https://doi.org/10.1016/s0002-9343\(00\)00503-9](https://doi.org/10.1016/s0002-9343(00)00503-9)
 21
- 22 Thompson, B., Gaitatzis, K., Janse de Jonge, X., Blackwell, R., & Koelmeyer, L. A. (2021).
 23 Manual lymphatic drainage treatment for lymphedema: a systematic review of the
 24 literature. *Journal of cancer survivorship : research and practice*, 15(2), 244–258.
 25 <https://doi.org/10.1007/s11764-020-00928-1>
 26
- 27 Torgbenu E, Luckett T, Buhagiar MA, Phillips JL. Guidelines Relevant to Diagnosis,
 28 Assessment, and Management of Lymphedema: A Systematic Review. *Adv Wound
 29 Care (New Rochelle)*. 2023;12(1):15-27. doi:10.1089/wound.2021.0149
 30
- 31 Torres Lacomba, M., Yuste Sánchez, M. J., Zapico Goñi, A., Prieto Merino, D., Mayoral
 32 del Moral, O., Cerezo Téllez, E., & Minayo Mogollón, E. (2010). Effectiveness of early
 33 physiotherapy to prevent lymphoedema after surgery for breast cancer: randomised,
 34 single blinded, clinical trial. *BMJ (Clinical research ed.)*, 340, b5396
 35
- 36 Torres-Lacomba, M., Navarro-Brazález, B., Prieto-Gómez, V., Ferrandez, J. C., Bouchet,
 37 J. Y., & Romay-Barrero, H. (2020). Effectiveness of four types of bandages and
 38 kinesiotope for treating breast-cancer-related lymphoedema: a randomized, single-
 39 blind, clinical trial. *Clinical rehabilitation*, 34(9), 1230–1241.
 40 <https://doi.org/10.1177/0269215520935943>

- 1 Tsai, H. J., Hung, H. C., Yang, J. L., Huang, C. S., & Tsauo, J. Y. (2009). Could Kinesio
 2 tape replace the bandage in decongestive lymphatic therapy for breast-cancer-related
 3 lymphedema? A pilot study. *Supportive care in cancer : official journal of the*
 4 *Multinational Association of Supportive Care in Cancer*, 17(11), 1353–1360.
 5 <https://doi.org/10.1007/s00520-009-0592-8>
 6
- 7 Tunkel, R. S., & Lachmann, E. (1998). Lymphedema of the limb. An overview of treatment
 8 options. *Postgraduate medicine*, 104(4), . <https://doi.org/10.3810/pgm.1998.10.450>
 9
- 10 Vignes, S., Blanchard, M., Arrault, M., & Porcher, R. (2013). Intensive complete
 11 decongestive physiotherapy for cancer-related upper-limb lymphedema: 11 days
 12 achieved greater volume reduction than 4. *Gynecologic oncology*, 131(1), 127–130.
 13 <https://doi.org/10.1016/j.ygyno.2013.07.101>
 14
- 15 Vignes, S., Porcher, R., Arrault, M., & Dupuy, A. (2007). Long-term management of breast
 16 cancer-related lymphedema after intensive decongestive physiotherapy. *Breast cancer*
 17 *research and treatment*, 101(3), 285–290. <https://doi.org/10.1007/s10549-006-9297-6>
 18
- 19 Wang Y, Ge Y, Xing W, et al. The effectiveness and safety of low-level laser therapy on
 20 breast cancer-related lymphedema: An overview and update of systematic reviews.
 21 *Lasers Med Sci.* 2022;37(3):1389-1413. doi:10.1007/s10103-021-03446-3
 22
- 23 Wang L, Shi YX, Wang TT, Chen KX, Shang SM. Breast cancer-related and resistance
 24 exercise: An evidence-based review of guidelines, consensus statements and systematic
 25 reviews. *J Clin Nurs.* 2023 May;32(9-10):2208-2227.
 26
- 27 Watanabe, Y., Koshiyama, M., Seki, K., Nakagawa, M., Ikuta, E., Oowaki, M., &
 28 Sakamoto, S. I. (2019). Development and Themes of Diagnostic and Treatment
 29 Procedures for Secondary Leg Lymphedema in Patients with Gynecologic
 30 Cancers. *Healthcare (Basel, Switzerland)*, 7(3), 101.
 31 <https://doi.org/10.3390/healthcare7030101>
 32
- 33 Yeung W, Semciw AI. Aquatic Therapy for People with Lymphedema: A Systematic
 34 Review and Meta-analysis. *Lymphat Res Biol.* 2018 Feb;16(1):9-19
 35
- 36 Zasadzka, E., Trzmiel, T., Kleczewska, M., & Pawlaczyk, M. (2018). Comparison of the
 37 effectiveness of complex decongestive therapy and compression bandaging as a
 38 method of treatment of lymphedema in the elderly. *Clinical interventions in aging*, 13,
 39 929–934. <https://doi.org/10.2147/CIA.S159380>
 40
- 41 Zuther E. and Norton, S. (2013). *Pathology. Lymphedema Management: The*
 42 *Comprehensive Guide for Practitioners (3rd ed)*. Theime Medical Publishers, Inc.